



(51) International Patent Classification:

A61L 27/50 (2006.01) A61K 9/127 (2006.01)
A61K 9/00 (2006.01) A61K 31/685 (2006.01)

(21) International Application Number:

PCT/IL2018/050923

(22) International Filing Date:

21 August 2018 (21.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/548,429 22 August 2017 (22.08.2017) US

(71) Applicant: **MOEBIUS MEDICAL LTD.** [IL/IL]; 27
HaBarzel Street, 67910 Tel Aviv (IL).

(72) Inventors: **BARENHOLZ, Yechezkel**; 18 Neve Shaanan
Street, 9370719 Jerusalem (IL). **DOLEV, Yaniv**; 8 Moshe
Dayan Street, 4358008 Raanana (IL). **TURGEMAN,**
Keren; Derech Carmit St. 10, Apt. 22, Kiryat Yovel,
9574569 Jerusalem (IL). **SARFATI, Gadi**; Beit Guvrin,

7937000 Beit Guvrin (IL). **HERSHKOVITZ, Maty Ayal**;
6 Bilu, 4642416 Herzliya (IL).

(74) Agent: **WEBB, Cynthia** et al.; WEBB & CO., P.O. BOX
2189, 7612101 REHOVOT (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: LIPOSOMAL FORMULATION FOR JOINT LUBRICATION




FIGURE 1

(57) Abstract: The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C 12 -C 18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C 12 -C 18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20° C to about 39° C and the joint has a joint temperature which is above the phase transition temperature.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

LIPOSOMAL FORMULATION FOR JOINT LUBRICATION

FIELD OF THE INVENTION

The present invention relates to liposomal pharmaceutical compositions wherein the phospholipids themselves are the sole active pharmaceutical agents, and their therapeutic use for joint lubrication.

BACKGROUND OF THE INVENTION

Joint dysfunctions affect a very large portion of the population. Sufficient biolubrication is a prerequisite for proper joint mobility, which is crucial for prevention and amelioration of degradative changes of the joint.

A common joint dysfunction is osteoarthritis (OA), with prevalence exceeding 20 million in the United States alone. Current treatment focuses on reducing overloading of joints, physiotherapy, and alleviation of pain and inflammation, usually by systemic or intra-articular administration of drugs.

Articular cartilage forms a smooth, tough, elastic and flexible surface that facilitates bone movement. The synovial space is filled with the highly viscous synovial fluid (SF), containing hyaluronic acid (HA) and the glycoprotein lubricin. HA is a polymer of D-glucuronic acid and D-N-acetylglucosamine, which is highly unstable and degrades under the inflammatory conditions of OA (Nitzan, D.W., Kreiner, B. & Zeltser, R. TMJ lubrication system: its effect on the joint function, dysfunction, and treatment approach. *Compend. Contin. Educ. Dent.* **25**, 437-444 (2004); Yui, N., Okano, T. & Sakurai, Y. Inflammation responsive degradation of crosslinked hyaluronic acid gels. *J. Control. Release* **22**, 105-116 (1992)). Lubricin is composed of ~44% proteins, ~45% carbohydrates and ~11% phospholipids (PLs), of which ~41% are phosphatidylcholines (PCs), ~27% phosphatidylethanolamines (PEs) and ~32% sphingomyelins. These PLs are referred to as “surface-active phospholipids” (SAPL).

Boundary lubrication, in which layers of lubricant molecules separate opposing surfaces, occurs under loading of articular joints. Several different substances have been proposed as the native boundary lubricants in articular cartilage, including HA and lubricin. Pickard et al. and Schwartz and Hills demonstrated that phospholipids defined as surface active phospholipids of lubricin facilitate joint lubrication in articular cartilage (Pickard, J.E., Fisher, J., Ingham, E. & Egan, J. Investigation into the effects of proteins and lipids on the frictional properties of

articular cartilage. *Biomaterials* **19**, 1807-1812 (1998); Schwarz, I.M. & Hills, B.A. Surface-active phospholipid as the lubricating component of lubricin. *Br. J. Rheumatol.* **37**, 21-26 (1998)). Hills and coworkers demonstrated that OA joints have a SAPL deficiency, and that injection of the surface-active phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) into joints of OA patients resulted in mobility improvement lasting up to 14 weeks without major side effects (Vecchio, P., Thomas, R. & Hills, B.A. Surfactant treatment for osteoarthritis. *Rheumatology (Oxford)* **38**, 1020-1021 (1999); Gudimelta, O.A., Crawford, R. & Hills, B.A. Consolidation responses of delipidized cartilage. *Clin. Biomech.* **19**, 534-542 (2004)). In another study, utilizing a unique cryogenic cartilage preservation technique, Watanabe et al. observed lipidic globular vesicles on the surface of healthy cartilage, which are assumed to play a major role in lubrication (Watanabe, M. et al. Ultrastructural study of upper surface layer in rat articular cartilage by "in vivo cryotechnique" combined with various treatments. *Med. Elect. Microsc.* **33**, 16-24 (2000)). Kawano et al. and Forsey et al., using animal models, have shown that use of high molecular weight HA (~2000 kDa) combined with DPPC improved lubricating ability of the latter (Kawano, T. et al. Mechanical effects of the intraarticular administration of high molecular weight hyaluronic acid plus phospholipid on synovial joint lubrication and prevention of articular cartilage degeneration in experimental osteoarthritis. *Arthritis Rheum.* **48**, 1923-1929 (2003); Forsey, R.W. et al. The effect of hyaluronic acid and phospholipid based lubricants on friction within a human cartilage damage model. *Biomaterials* **27**, 4581-4590 (2006)).

US Patent 6,800,298 discloses dextran-based hydrogel compositions containing lipids, particularly phospholipids, for lubrication of mammalian joints.

US Patent Application 2005/0123593 is directed to a composition comprising glycosaminoglycans encapsulated in a liposomal delivery system for intraarticular administration for the treatment of osteoarthritis.

US Patent 8,895,054 concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes consisting essentially of phospholipid membranes having a phase transition temperature in the range of about 20°C to about 39°C.

Commercially available pharmaceutical compositions for the prevention and treatment of osteoarthritis, which are based on hyaluronic acid as an active ingredient, include, *inter alia*, Antalvisc®, Kartilage® and Kartilage® Cross. Said pharmaceutical compositions include mannitol in addition to HA. It was found that mannitol has an ability to reduce HA degradation

under oxidative stress and therefore can be used to significantly increase the intra-articular residence time of the injected HA and improve viscosupplementation effectiveness of HA-based intra-articular injections (M. Rinaudo, B. Lardy, L. Grange, and T. Conrozier, *Polymers* **2014**, 6, 1948-1957). A clinical study comparing both safety and efficacy of an intra-articular viscosupplement made of intermediate molecular weight (MW) hyaluronic acid mixed with high concentration of mannitol and a high MW HA alone (Bio-HA), in patients with knee osteoarthritis revealed that the mannitol-containing viscosupplement was not less effective than its comparator Bio-HA, in terms of pain relief and function improvement over six months, without inducing more side effects (Conrozier, Thierry et al. *The Knee*, **2016**, 23 (5), 842 – 848). The effect of mannitol on the efficacy of HA-based viscosupplement compositions was also studied by Eymard et al., (Eymard F, Bossert M, Lecurieux R, Maillet B, Chevalier X, et al. (2016) Addition of Mannitol to Hyaluronic Acid may Shorten Viscosupplementation Onset of Action in Patients with Knee Osteoarthritis: Post-Hoc Analysis of A Double-blind, Controlled Trial. *J Clin Exp Orthop* 2: 21) and Conrozier, T. et al. (Role of high concentrations of mannitol on the stability of hyaluronan in an oxidative stress model induced by xanthine/xanthine oxidase Osteoarthritis and Cartilage, Volume 22 , S478). Ferraccioli et al. have showed that ultra-violet illumination of synovial fluid could be a helpful method for the screening of the free radical scavenging effect of drugs, as it induces a viscosity fall due to the production of free radicals. The protection of the viscosity of human synovial fluid was mediated by Superoxide dismutase, mannitol and catalase (G.F. Ferraccioli, U. Ambanelli, P. Fietta, N. Giudicelli, C. Giori, Decrease of osteoarthritic synovial fluid viscosity by means of u.v. illumination: A method to evaluate the free radical scavenging action of drugs, *Biochemical Pharmacology*, 30, (13) 1981, 1805-1808).

International Patent Application WO2012/001679 is directed to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection, comprising an active polyol ingredient, which polyol active ingredient is xylitol. The efficacy of xylitol was compared with the efficacy of mannitol and glycerol for the prevention of joint irritation, and it was disclosed that a solution of mannitol or glycerol did not prevent irritation, when injected by intra-articular injection into a rabbit's knee.

US Patent Application 2014/0038917 is directed to a sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint of a subject,

in the form of a gel comprising: hyaluronic acid, or one of its salts, and a polyol, preferably, sorbitol at a concentration equal or higher than 7 mg/ml.

International Patent Application WO2003/000191 relates to a composition and method for treating arthritis comprising one or more glycosaminoglycans in combination with one or more hyaluronidase inhibitors, wherein the hyaluronidase inhibitors can be selected from heparan sulphate, dextran sulphate and xylose sulphate, and wherein hyaluronic acid can be co-encapsulated with a hyaluronidase inhibitor in liposomes.

Injectable HA compositions are known to have various side effects, such as difficulty with moving, muscle pain or stiffness, pain in the joints and swelling or redness in the joint. Some of the side effects of Antalvisc® include transient pain and swelling of the injected joint following injection.

There remains, therefore, an unmet need for an efficient pharmaceutical composition for joint lubrication, which would provide a long-lasting effect, while reducing the probability of side effects associated with intra-articular administration.

SUMMARY OF THE INVENTION

The present invention provides a liposomal formulation for introduction into synovial joints to provide lubrication in order to reduce pain and irritation and improve or restore joint mobility. The liposomal formulation is adapted specifically for intra-articular delivery. The pharmaceutical composition of the present invention comprises liposomes, as an active ingredient, which comprise phospholipid membranes having a phase transition temperature which is slightly lower than the physiological temperature. The liposomes are therefore in the liquid-disordered (LD) phase when administered to the synovial joint. The pharmaceutical composition further comprises a tonicity agent which is a polyol. The tonicity agent is being used to reduce local irritation by preventing osmotic shock at the site of application.

The present invention is based in part on the surprising discovery that non-ionic tonicity agents, which were added to the liposomal composition, provided enhanced lubrication as compared to an ionic tonicity agent. In particular, addition of mannitol to the liposomal formulation improved the lubrication efficacy of the composition, whereas the use of sodium chloride resulted in decreased lubrication efficiency of the liposomes. The effect of mannitol is even more surprising in view of the fact that the pharmaceutical compositions do not comprise any additional pharmaceutically active agent besides the phospholipids themselves, and in

particular, do not contain hyaluronic acid, the activity of which is known to be enhanced by the addition of polyols. Addition of a different non-ionic polyol, including specifically glycerol, also resulted in enhancement of the lubrication ability of the liposomal formulation, as compared to the use of sodium chloride, though to a less pronounced extent.

5 Thus, in accordance with a first aspect, the present invention provides a pharmaceutical composition comprising a tonicity agent, comprising a polyol; and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C₁₂-C₁₈ hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C₁₂-C₁₈ hydrocarbon chain, wherein the at least one membrane has
10 a phase transition temperature in the range of about 20°C to about 39°C; wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent. The pharmaceutical composition is useful in the lubrication of a mammalian joint having a temperature which is above the phase transition temperature. According to some embodiments, the tonicity agent is non-ionic. According to further embodiments, the polyol is selected from
15 mannitol and glycerol. According to a specific embodiment, the tonicity agent comprises mannitol.

 In another aspect there is provided a method for lubricating a joint of a mammal, the method comprising: administering into a cavity of the joint a pharmaceutical composition comprising a tonicity agent, comprising a polyol; and liposomes comprising at least one
20 membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C₁₂-C₁₈ hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C₁₂-C₁₈ hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C; wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent,
25 wherein the joint has a joint temperature which is above the phase transition temperature. According to some embodiments, the tonicity agent is non-ionic. According to further embodiments, the polyol is selected from mannitol and glycerol. According to a specific embodiment, the tonicity agent comprises mannitol.

 In another aspect there is provided a method for the treatment of pain or irritation in a
30 joint of a subject having an articular disorder, the method comprising lubricating a joint of said subject by administering into a cavity of the joint a pharmaceutical composition comprising a

tonicity agent comprising a polyol; and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C₁₂-C₁₈ hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C₁₂-C₁₈ hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C; wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent, and wherein the joint has a joint temperature which is above the phase transition temperature. According to some embodiments, the tonicity agent is non-ionic. According to further embodiments, the polyol is selected from mannitol and glycerol. According to a specific embodiment, the tonicity agent comprises mannitol.

In another aspect, the invention provides the use of a tonicity agent, comprising a polyol; and liposomes consisting essentially of at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C₁₂-C₁₈ hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C₁₂-C₁₈ hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C, for the preparation of a pharmaceutical composition for lubrication of a mammalian joint having a temperature above said phase transition temperature, wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent. According to some embodiments, the tonicity agent is non-ionic. According to further embodiments, the polyol is selected from mannitol and glycerol. According to a specific embodiment, the tonicity agent comprises mannitol.

In some embodiments, the polyol does not include xylitol.

In some embodiments, the polyol is present in the pharmaceutical composition in a weight percent ranging from about 5% (w/w) to about 50% (w/w) of the dry weight of the pharmaceutical composition. In some embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 20% (w/w) to about 40% (w/w) of the dry weight of the pharmaceutical composition. In some embodiments, glycerol is present in the pharmaceutical composition in a weight percent ranging from about 5% (w/w) to about 25% (w/w) of the dry weight of the pharmaceutical composition. In some embodiments, the phospholipids are present in the pharmaceutical composition in a weight percent ranging from about 50% (w/w) to about 95% (w/w) of the dry weight of the pharmaceutical composition.

In some embodiments, the pharmaceutical composition further comprises a fluid medium in which the liposomes are dispersed or suspended. In further embodiments, the polyol is

dispersed or dissolved in said fluid medium. In still further embodiments, mannitol is dissolved in said fluid medium. The fluid medium can be selected from buffer and water. In certain embodiments, said buffer comprises a histidine buffer or phosphate buffered saline. Each possibility represents a separate embodiment of the invention. In certain embodiments, said
5 buffer comprises a histidine buffer.

In some embodiments, the pharmaceutical composition is in the form of a pharmaceutically acceptable suspension comprising liposomes suspended in the fluid medium.

According to some embodiments, the concentration of the polyol inside the liposome is essentially the same as the concentration of the polyol in the medium outside the liposome.

10 In some embodiments, the polyol is present in the pharmaceutical composition in a weight percent ranging from about 0.05% (w/w) to about 10% (w/w) of the total weight of the pharmaceutical composition. In further embodiments, the weight percent of the polyol ranges from about 0.1% (w/w) to about 7% (w/w). In still further embodiments, the weight percent of the polyol ranges from about 1% (w/w) to about 5% (w/w).

15 In some embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 0.1% (w/w) to about 7% (w/w) of the total weight of the pharmaceutical composition. In further embodiments, the weight percent of mannitol ranges from about 1% (w/w) to about 7% (w/w).

20 In some embodiments, glycerol is present in the pharmaceutical composition in a weight percent ranging from about 0.05% (w/w) to about 5% (w/w) of the total weight of the pharmaceutical composition. In further embodiments, the weight percent of glycerol ranges from about 0.5% (w/w) to about 5% (w/w).

In some embodiments, the pharmaceutical composition has osmolality in the range from about 200 to about 600 mOsm. In certain embodiments, the pharmaceutical composition has
25 osmolality of about 300 mOsm. In certain such embodiments, the pharmaceutical composition is isotonic.

In some embodiments, the pharmaceutical composition has a pH of about 5-8.

30 In some embodiments, the weight ratio between the liposomes and the polyol ranges from about 15:1 to about 1:1. In further embodiments, the weight ratio between the liposomes and mannitol ranges from about 10:1 to about 1:1. In additional embodiments, the weight ratio between the liposomes and glycerol ranges from about 15:1 to about 2:1.

According to some embodiments, the liposomes have more than one membrane. In certain such embodiments, the liposomes are multilamellar vesicles (MLV).

In some embodiments, the GPL comprises two acyl chains. In further embodiments, said chains are selected from the group consisting of C₁₄, C₁₅, C₁₆ and C₁₈ acyl chains. In certain
5 embodiments, at least one of said hydrocarbon chains is a saturated hydrocarbon chain. In further
embodiments, the two hydrocarbon chains are saturated.

In some embodiments, the PL is a phosphatidylcholine (PC). In further embodiments, the at least one membrane comprises 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC).

In some embodiments, the at least one membrane further comprises a PC selected from
10 the group consisting of 1, 2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC), 1,2-
dipentadecanoyl-*sn*-glycero-3-phosphocholine (C15), 1,2-distearoyl-*sn*-glycero-3-
phosphocholine (DSPC), and N-palmitoyl-D-*erythro*-sphingosylphosphorylcholine (D-*erythro*
C16). In some embodiments, the mole percent of DMPC in the at least one membrane ranges
from about 10% to about 75%.

15 In some embodiments, the at least one membrane comprises DMPC and DPPC. In further
embodiments, the mole percent ratio of DMPC to DPPC is in the range of about 25:75 to about
70:30. In certain embodiments, the mole percent ratio of DMPC to DPPC is about 45:55.

In some embodiments, the at least one membrane comprises DMPC and C15. In further
embodiments, the mole percent ratio of DMPC to C15 is in the range of about 25:75 to about
20 45:55.

In some embodiments, the at least one membrane comprises DMPC and DSPC. In further
embodiments, the mole percent ratio of DMPC to DSPC is about 75:25.

In some embodiments, the at least one membrane comprises DMPC and D-*erythro* C16.
In further embodiments, the mole percent ratio of DMPC to D-*erythro* C16 is in the range of
25 about 10:90 to about 25:75.

In some embodiments, the at least one membrane comprises C15.

The total concentration of the phospholipids in the pharmaceutical composition according
to some embodiments of the invention ranges from about 50 to about 300 mM. In certain
embodiments, the total concentration of the phospholipids ranges from about 100 mM to about
30 200 mM.

In some embodiments, the phospholipids are present in the pharmaceutical composition
in a weight percent ranging from about 0.5% (w/w) to about 30% (w/w) of the total weight of the

pharmaceutical composition. In further embodiments, the weight percent of the phospholipids ranges from about 3% (w/w) to about 30% (w/w).

In some embodiments, the liposomes have a mean diameter of between about 0.5 μm to about 10 μm .

5 In certain embodiments, the at least one membrane has the phase transition temperature of about 30°C to about 35°C.

In some embodiments, the temperature of the joint is in the range of about 1 – 15 °C above said phase transition temperature.

10 In some currently preferred embodiments, the pharmaceutical composition is being essentially free of hyaluronic acid.

In certain embodiments, the liposomes consist essentially of the at least one membrane comprising at least one phospholipid (PL), as detailed hereinabove.

15 In some embodiments, the pharmaceutical composition comprises MLV liposomes which membranes consist essentially of DMPC and DPPC; mannitol; and histidine buffer. In further embodiments, DMPC is present in the pharmaceutical composition in a weight percent ranging from about 1% (w/w) to about 10% (w/w) of the total weight of the pharmaceutical composition. In still further embodiments, DPPC is present in the pharmaceutical composition in a weight percent ranging from about 2% (w/w) to about 12% (w/w) of the total weight of the pharmaceutical composition. In yet further embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 1% (w/w) to about 7% (w/w) of the total weight of the pharmaceutical composition.

20 In some embodiments, the lubrication of the joint is for the treatment of an articular disorder or symptoms arising therefrom. In further embodiments, the articular disorder is selected from the group consisting of arthritis, osteoarthritis, osteoarthritis in rheumatoid arthritis patients, traumatic joint injury, locked joint, sports injury, status post arthrocentesis, arthroscopic surgery, open joint surgery, and joint replacement. Each possibility represents a separate embodiment of the invention. In certain embodiments, the pharmaceutical composition is for the reduction of knee joint pain in osteoarthritis patients.

In some embodiments, the lubrication is for preventing joint wear.

30 According to specific embodiments the pharmaceutical composition is a parenteral pharmaceutical composition comprising a suspension of liposomes. The pharmaceutical composition can be in a form suitable for administration by intra-articular injection, arthroscopic

administration or by surgical administration. Each possibility represents a separate embodiment of the invention.

The pharmaceutical composition according to the various embodiments of the invention may be administered in a dose of from about 0.5 ml to about 10 ml. In further embodiments, the pharmaceutical composition is administered in a dose of from about 1 ml to about 6 ml. In certain embodiments, the pharmaceutical composition is administered in a dose of about 3 ml.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 20 mg to about 350 mg mannitol. In a certain embodiment, one dosage unit of the pharmaceutical composition comprises about 120 mg mannitol.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 50 mg to about 1000 mg phospholipids. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 50 mg to about 500 mg DPPC. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 40 mg to about 300 mg DMPC.

Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows raw Differential Scanning Calorimetry (DSC) thermograms of isotonic and hypotonic liposomal compositions comprising DMPC/DPPC.

Figure 2 shows raw Differential Scanning Calorimetry (DSC) thermograms of isotonic and hypotonic liposomal compositions comprising C15.

Figure 3 is a bar diagram graph showing the SO to LD phase transition temperature range of liposomes comprising different phospholipids mixtures assessed from the DSC scans. Grey area indicates the temperature range of 20 °C – 39 °C.

Figure 4 shows profiles of cartilage pins before and after wear test in protein-based liquid. Position of appearing subchondral bone is marked by arrow. The scale does not show the effective height as the profiles are shifted for better visibility.

Figure 5A-5B show optical images of cartilage pin #9 before (**Figure 5A**) and 12 hours after (**Figure 5B**) wear testing in protein-based liquid. Besides the outer cartilage ring, subchondral bone appeared where cartilage was worn through (indicated by arrow).

Figure 6 shows profiles of cartilage pins before and after wear test in liposomal composition. The scale does not show the effective height as the profiles are shifted for better visibility.

Figure 7A-7B show optical images of cartilage pin #14 before (**Figure 7A**) and 6 hours after (**Figure 7B**) wear testing in liposomal composition.

Figure 8A-8B show optical images of cartilage pin #17 before (**Figure 8A**) and 12 hours after (**Figure 8B**) wear testing in liposomal composition.

Figure 9A-9B show a graphical comparison of mass loss (**Figure 9A**) and height loss (**Figure 9B**) of the protein based vs. the liposomal composition. The error bars are a rough estimate of the measurement precision.

Figure 10A-10B show profiles of the cartilage surfaces before and after the wear test in protein-based liquid (**Figure 10A**) and in liposomal composition (**Figure 10B**).

Figure 11 shows roughness parameters Ra (●), Rk (◆), Rpk (▲) and Rvk (▼), before (t=0) and after wear testing (6h and 12h) for pins 13 to 18 tested in the liposomal composition, wherein Ra is an arithmetic mean deviation of roughness profile and Rk is kernel roughness depth (roughness depth excluding the value of the highest peak (Rpk) and the lower valley (Rvk)).

DETAILED DESCRIPTION OF SOME EMBODIMENTS

The present invention provides a liposomal formulation for use in the lubrication of mammalian joints, said lubrication providing reduced pain and irritation and allowing to improve or restore joint mobility and reduce wear of the joint. The pharmaceutical composition can further be used for the treatment, management or prevention of an articular disorder or condition. The pharmaceutical composition according to the principles of the invention is based on a liposomal composition, having a defined phase transition temperature of the liposomes' membranes, said temperature being below the temperature of the joint.

The term “phase transition temperature”, as used herein, refers in some embodiments, to a temperature at which solid ordered (SO) to liquid disordered (LD) phase transition of the liposome occurs. The phase transition temperature of the liposomes can be evaluated by Differential Scanning Calorimetry (DSC). Various parameters of the DSC thermogram which
5 can be examined to assess the phase transition temperature include T_{on} , which represents the temperature at which the SO-LD phase transition is initiated and T_{off} , which represents the temperature at which the SO-LD phase transition ends during heating scans, and T_p , and T_m , which represent the temperature at which the maximum change in the heat capacity during the pre-transition (T_p) and main transition (T_m) occurs, respectively.

10 Multilamellar vesicle liposomes composed of various PCs, with two C_{12} - C_{16} hydrocarbon chains where previously shown to be effective cartilage lubricants and wear reducers at temperature slightly above (e.g. about 1°C , 2°C , 3°C , 5°C , 8°C , 11°C and at times up to about 15°C) the SO-to-LD phase transition temperature (as detailed in the US Patent 8,895,054, the contents of which is hereby incorporated by reference in its entirety). Pharmaceutical
15 compositions of the present invention further comprise a non-ionic tonicity agent, which increases osmolarity of the composition.

It was surprisingly found that lubrication efficiency of the pharmaceutical composition comprising a non-ionic polyol was significantly higher as compared to a pharmaceutical composition comprising an ionic tonicity agent, and in particular, sodium chloride salt. The
20 positive effect of the polyols as compared to sodium chloride was entirely unforeseen, since the pharmaceutical composition of the invention is not based on hyaluronic acid, activity of which is known to be enhanced by the addition of polyols.

The inventors have further shown that the addition of mannitol did not alter the phase transition temperature of the liposome membranes. Without wishing to being bound by theory or
25 mechanism of action, it can be assumed that the surprising effect of the polyol addition is not directly related to the phase transition temperature of the liposome, which has been previously reported to be the essential feature affording for the lubrication ability thereof.

Thus, in accordance with an aspect of the invention, there is provided a pharmaceutical composition comprising a tonicity agent, comprising a polyol; and a liposome comprising at
30 least one phospholipid (PL) selected from glycerophospholipid (GPL) or sphingolipid (SPL) and having a phase transition temperature in the range of about 20°C to about 39°C , wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent. In

some embodiments, the pharmaceutical composition is for use in the lubrication of a mammalian joint.

In another aspect, there is provided a method for lubricating a joint of a mammal, the method comprising: administering into a cavity of the joint a pharmaceutical composition comprising: a tonicity agent, comprising a polyol; and a liposome comprising at least one phospholipid (PL) selected from glycerophospholipid (GPL) or sphingolipid (SPL) having a phase transition temperature in the range of about 20°C to about 39°C, wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent.

In another aspect there is provided a method for the treatment of pain or irritation in a joint of a subject having an articular disorder, the method comprising lubricating a joint of said subject by administering into a cavity of the joint a pharmaceutical composition comprising: a tonicity agent, comprising a polyol; and a liposome comprising at least one phospholipid (PL) selected from glycerophospholipid (GPL) or sphingolipid (SPL) having a phase transition temperature in the range of about 20°C to about 39°C, wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent.

In another aspect, the invention provides the use of a tonicity agent, comprising a polyol and a liposome comprising at least one phospholipid (PL) selected from glycerophospholipid (GPL) or sphingolipid (SPL) having a phase transition temperature in the range of about 20°C to about 39°C, for the preparation of a pharmaceutical composition for lubrication of a mammalian joint, wherein the pharmaceutical composition is essentially free of an additional pharmaceutically active agent.

The term “tonicity agent”, as used herein, refers in some embodiments to a tonicity agent suitable for use in pharmaceutical compositions for intra-articular injection.

In some embodiments, the tonicity agent is non-ionic. In some embodiments, the polyol is a linear polyol. In some embodiments, the polyol is a cyclic polyol. Non-limiting examples of non-ionic polyols suitable for use in the pharmaceutical composition of the invention include mannitol, glycerol, dextrose, lactose, and trehalose.

In some currently preferred embodiments, the polyol is mannitol. Mannitol is a well-known and low-cost excipient, frequently used by formulators in various types of pharmaceutical compositions. As mentioned hereinabove, mannitol has been used in combination with hyaluronic acid in pharmaceutical compositions for joint lubrication. Mannitol has also been

reported as being useful in cryopreservation of liposomes (Talsma H, van Steenberg MJ, Salemink PJ, Crommelin DJ, Pharm Res. **1991**, 8 (8):1021-6).

In some embodiments, the tonicity agent comprises glycerol.

5 In some embodiments, the pharmaceutical composition comprises a combination of polyols, i.e., a combination of mannitol and glycerol. The pharmaceutical composition can further include a combination of a polyol with an additional tonicity agent.

In some embodiments, the polyol does not include xylitol.

10 It is to be emphasized that according to some currently preferred embodiments, the tonicity agent is not encapsulated within the liposomes. The term “encapsulated”, as used herein, refers in some embodiments, to the concentration of the tonicity agent inside the liposome being substantially higher than in the medium outside the liposome. The term “inside the liposome” is to be understood as encompassing at least one inner aqueous phase of the liposome. The term “concentration” can include osmotic concentration. The term “substantially higher”, as used herein, refers in some embodiments to the difference in the concentration of at least about 90%.
15 In some embodiments, the polyol is not encapsulated within the liposomes. In further embodiments, mannitol is not encapsulated within the liposomes. In additional embodiments, glycerol is not encapsulated within the liposomes.

According to further embodiments, the concentration of the tonicity agent inside the liposome is essentially the same as the concentration of the tonicity agent in the medium outside
20 the liposome. The term “essentially the same”, as used herein, refers in some embodiments, to the difference in the concentration of less than about 15%. In further embodiments, the term “essentially the same” refers to the difference in the concentration of less than about 10%, less than about 5%, less than about 2.5%, or less than about 1%. Each possibility represents a separate embodiment of the invention.

25 According to further embodiments, the concentration of the polyol inside the liposome is essentially the same as the concentration of the polyol in the medium outside the liposome. According to still further embodiments, the concentration of mannitol inside the liposome is essentially the same as the concentration of mannitol in the medium outside the liposome. According to yet further embodiments, the concentration of the glycerol inside the liposome is
30 essentially the same as the concentration of glycerol in the medium outside the liposome.

In some embodiments, the liposomes are not freeze-dried. In further embodiments, the liposomes are not freeze-dried and/or thawed prior to the administration to the joint.

In some embodiments, the pharmaceutical composition further comprises a fluid medium. In some embodiments, the liposomes are dispersed or suspended in said fluid medium. In further embodiments the tonicity agent is dissolved or dispersed in said fluid medium. In further embodiments, mannitol or glycerol are dissolved in said fluid medium. In some
5 embodiments, the pharmaceutical composition is in a form of a pharmaceutically acceptable suspension comprising liposomes suspended in the fluid medium.

Further provided is a pharmaceutically acceptable suspension comprising the pharmaceutical composition according to the various embodiments hereinabove and further comprising a fluid medium.

10 In some embodiments, the polyol is present in the pharmaceutical composition in a weight percent ranging from about 5% (w/w) to about 50% (w/w), or from about 10% (w/w) to about 40% (w/w) of the dry weight of the pharmaceutical composition. In certain embodiments, the polyol is present in the pharmaceutical composition in a weight percent of about 30% (w/w) of the dry weight of the pharmaceutical composition. In additional embodiments, the polyol is
15 present in the pharmaceutical composition in a weight percent of about 15% (w/w) of the dry weight of the pharmaceutical composition.

In some embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 10% (w/w) to about 50% (w/w), or from about 20% (w/w) to about 50% (w/w) of the dry weight of the pharmaceutical composition. In further embodiments,
20 mannitol is present in the pharmaceutical composition in a weight percent of about 30% (w/w) of the dry weight of the pharmaceutical composition.

In some embodiments, glycerol is present in the pharmaceutical composition in a weight percent ranging from about 5% (w/w) to about 35% (w/w), or from about 5% (w/w) to about 25% (w/w) of the dry weight of the pharmaceutical composition. In further embodiments,
25 glycerol is present in the pharmaceutical composition in a weight percent of about 15% (w/w) of the dry weight of the pharmaceutical composition.

In some embodiments, the phospholipids forming the liposomes are present in the pharmaceutical composition in a weight percent ranging from about 50% (w/w) to about 95% (w/w), or from about 60% (w/w) to about 85% (w/w) of the dry weight of the pharmaceutical
30 composition. In further embodiments, the phospholipids are present in the pharmaceutical composition in a weight percent of about 70% (w/w) of the dry weight of the pharmaceutical composition. In further embodiments, the phospholipids are present in the pharmaceutical

composition in a weight percent of about 85% (w/w) of the dry weight of the pharmaceutical composition.

The term “dry weight”, as used herein, refers in some embodiments, to the weight of a pharmaceutical composition, which does not include a fluid medium. In further embodiments, the term “dry weight” refers to the weight of a pharmaceutical composition, which does not include water.

In some embodiments, the compositions of this invention are pharmaceutically acceptable. The term "pharmaceutically acceptable", as used herein, refers in some embodiments to any formulation which is safe, and provides the appropriate delivery for the desired route of administration of an effective amount of the active ingredient for use in the present invention. This term refers to the use of buffered formulations as well, wherein the pH is maintained at a particular desired value, ranging from pH 4.0 to pH 9.0, in accordance with the stability of the compounds and route of administration.

The fluid medium can be, therefore, selected from buffer, water, and salt solution. In some embodiments, the fluid medium comprises buffer. In certain embodiments, said buffer comprises a histidine buffer or phosphate buffered saline. Each possibility represents a separate embodiment of the invention. The concentration of histidine can range from about 0.5 mg/ml to about 10 mg/ml. In certain embodiments, the concentration of histidine is about 2 mg/ml. In some embodiments, the concentration of histidine ranges from about 1 mM to about 50 mM. In certain embodiments, the concentration of histidine is about 10 mM. Histidine can be present in the composition in the form of a dissolved hydrochloric or acetate salt. In certain embodiments, the pharmaceutical composition further comprises trace amounts of inorganic acids, such as, for example, hydrochloric acid.

The pH of the pharmaceutical composition can range between about 5 to about 8. In some embodiments, the pH ranges between about 6 and about 7. In certain embodiments, the pH of the pharmaceutical composition is about 6.5.

In some embodiments, the concentration of the polyol in the pharmaceutical composition ranges from about 0.5 to about 100 mg/ml. In further embodiments, the concentration of the polyol ranges from about 1 to about 70 mg/ml. In still further embodiments, the concentration of the polyol ranges from about 2.5 to about 60 mg/ml. In yet further embodiments, the concentration of the polyol ranges from about 5 to about 50 mg/ml. In still further embodiments,

the concentration of the polyol ranges from about 30 to about 50 mg/ml. In certain embodiments, the concentration of the polyol ranges from about 5 to about 30 mg/ml.

In some embodiments, the concentration of mannitol in the pharmaceutical composition ranges from about 1 mg/ml to about 70 mg/ml. In further embodiments, the concentration of mannitol ranges from about 10 mg/ml to about 70 mg/ml. In still further embodiments, the concentration of mannitol ranges from about 10 mg/ml to about 50 mg/ml. In certain embodiments, the concentration of mannitol is about 40 mg/ml. In additional embodiments, the concentration of mannitol is about 20 mg/ml.

In some embodiments, the concentration of glycerol in the pharmaceutical composition ranges from about 0.5 mg/ml to about 50 mg/ml. In further embodiments, the concentration of glycerol ranges from about 1 mg/ml to about 40 mg/ml. In still further embodiments, the concentration of glycerol ranges from about 5 mg/ml to about 30 mg/ml. In certain embodiments, the concentration of glycerol is about 20 mg/ml. In additional embodiments, the concentration of glycerol is about 10 mg/ml.

In some embodiments, the concentration of polyol in the pharmaceutical composition ranges from about 50 to about 500 mM. In further embodiments, the concentration of polyol ranges from about 100 to about 400 mM. In still further embodiments, the concentration of polyol ranges from about 200 to about 300 mM. The polyol can be selected from mannitol and glycerol.

In some embodiments, the polyol is present in the pharmaceutical composition in a weight percent ranging from about 0.05% (w/w) to about 10% (w/w), from about 0.1% (w/w) to about 7% (w/w), from about 0.5% (w/w) to about 10% (w/w), or from about 1% (w/w) to about 5% (w/w) of the total weight of the pharmaceutical composition. In certain embodiments, the weight percent of the polyol is about 4% (w/w). In additional embodiments, the weight percent of the polyol is about 2% (w/w).

In some embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 0.1% (w/w) to about 7% (w/w), from about 0.5% (w/w) to about 10% (w/w), or from about 1% (w/w) to about 7% (w/w) of the total weight of the pharmaceutical composition. In certain embodiments, the weight percent of mannitol is about 4% (w/w).

In some embodiments, glycerol is present in the pharmaceutical composition in a weight percent ranging from about 0.05% (w/w) to about 5% (w/w), or from about 0.5% (w/w) to about

5% (w/w) of the total weight of the pharmaceutical composition. In certain embodiments, the weight percent of glycerol is about 2% (w/w).

The term “total weight”, as used herein, refers in some embodiments to the weight of the pharmaceutical composition comprising the fluid medium. In further embodiments, the term “total weight” refers to the weight of the pharmaceutically acceptable suspension.

In some embodiments, the pharmaceutical composition has osmolality in the range from about 200 to about 600 mOsm. In further embodiments, the pharmaceutical composition has osmolality in the range from about 250 to about 500 mOsm. In further embodiments, the pharmaceutical composition has osmolality in the range from about 250 to about 400 mOsm. In certain embodiments, the pharmaceutical composition has osmolality of about 300 mOsm. In certain such embodiments, the pharmaceutical composition is isotonic.

In some embodiments, the weight ratio between the liposomes and the polyol ranges from about 30:1 to about 1:2. In further embodiments, the weight ratio between the liposomes and the polyol ranges from about 15:1 to about 2:1. In still further embodiments, the weight ratio between the liposomes and the polyol ranges from about 10:1 to about 2:1. In yet further embodiments, the weight ratio between the liposomes and the polyol ranges from about 6:1 to about 2:1. In additional embodiments, the weight ratio between the liposomes and the polyol ranges from about 10:1 to about 6:1.

In some embodiments, the weight ratio between the liposomes and mannitol ranges from about 10:1 to about 1:1. In further embodiments, the weight ratio between the liposomes and mannitol ranges from about 6:1 to about 2:1. In certain embodiments, the weight ratio between the liposomes and mannitol is about 4:1.

In some embodiments, the weight ratio between the liposomes and glycerol ranges from about 15:1 to about 2:1. In further embodiments, the weight ratio between the liposomes and glycerol ranges from about 12:1 to about 2:1. In still further embodiments, the weight ratio between the liposomes and glycerol ranges from about 10:1 to about 6:1.

In some embodiments, the pH of the pharmaceutical composition can be adjusted by the use of an inorganic acid or base. The non-limiting examples of suitable inorganic bases include sodium hydroxide and potassium hydroxide. Each possibility represents a separate embodiment of the invention.

In accordance with some embodiments of the invention, the GPL comprises a phosphocholine headgroup (phosphatidylcholine, PC-based lipid) or a phosphoglycerol

headgroup (phosphatidylglycerol, PG-based lipid), and the SPL is a ceramide (N-acyl sphingosine carrying a phosphocholine headgroup, also referred to as N-acyl sphingosine-phosphocholine (SM-based lipid)).

PCs and SMs are zwitterionic phospholipids with cationic choline and anionic diester phosphate moieties (constituting the phosphocholine head group). The hydrophobic part of the PC and PG includes 2 hydrocarbon (e.g. acyls and alkyls) chains. The SM also has two hydrophobic hydrocarbon chains of which one is the chain of the sphingoid base itself and the other is N-acyl chain. PC, SM and PG in which the hydrocarbon chains is above 12 carbon atoms are all cylinder like in shape as their packing parameter is in the range of 0.74-1.0. They form lipid bilayers which become highly hydrated and vesiculate to form lipid vesicles (liposomes) above the SO to LD phase transition temperature. The PC and PG liposome bilayers can be either in a solid ordered (SO) phase, or in a liquid disordered (LD). The transformation between the SO to LD phases involves an endothermic, first order phase transition referred to as the main phase transition. T_m is the temperature in which the maximum change in the heat capacity change during the SO to LD phase transition occurs. T_m and the temperature range of the SO to LD phase transition of PLs depend, *inter alia*, on PL hydrocarbon chain composition. In the LD phase (but not in the SO phase), the charged phosphocholine and phosphoglycerol head group are highly hydrated.

In some embodiments, the term “phase transition temperature” refers to the T_m . In other embodiments, the term “phase transition temperature” refers the temperature range of the SO to LD phase transition.

It is further noted that PGs and SM have T_m that are similar to that of the corresponding PC (the same length of substituting hydrocarbon chain(s)). For instance, the T_m of 1,2-dimyristoyl-*sn*-glycero-3-phosphorylglycerol (DMPG) is identical to that of DMPC, namely, 23°C, and that of 1,2-dipalmitoyl-*sn*-glycero-3-phosphorylglycerol (DPPG) or N-palmitoyl SM is identical to that of DPPC, namely, 41°C. Thus, while the following examples make use mainly of PC-based lipids, the PL in accordance with the invention may also be a PG- or SM-based lipid.

In accordance with the principles of the invention, a mixture of two or more PLs (e.g. two different PCs, a PC with PG, two different PGs, two SM, a PC or PG with SM, etc.) may be used, as long as the mixture formed is in a LD state, when *in situ* (e.g., at the articular region of a healthy or dysfunctioning joint).

In some particular embodiments, the liposome comprises a PC. In further particular embodiments, the liposome comprises a combination of two different PCs. In other particular embodiments, the liposome comprises a combination of a PC and SM.

In some embodiments, the liposomes are characterized in that they comprise at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL) having two, being the same or different, C₁₂-C₁₈ hydrocarbon chains and a sphingolipid (SPL) having a C₁₂-C₁₈ hydrocarbon chain. The phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, is within a temperature range of about 20°C to about 39°C. The liposomes are used to lubricate joints that have a joint temperature that is higher than the phase transition temperature. Accordingly, the liposomes are in an LD phase within the joint.

It is noted that the above conditions are cumulative, namely, the selection of PL (either a single PL or a combination of PL with additional PLs) contained in the liposome is so that the liposome will have SO-LD phase transition temperature between about 20°C to about 39°C.

The GPL or SPL can have alkyl, alkenyl or acyl C₁₂ to C₁₈ hydrocarbon chain. In the case of GPL, the two chains may be the same or different. In some embodiments, the GPL has C₁₂-C₁₆ hydrocarbon chains. In additional embodiments, the SPL has C₁₂-C₁₆ hydrocarbon chains.

One particular embodiment concerns the pharmaceutical composition comprising liposomes having GPL or SPL with at least one C₁₄ acyl chain. Another particular embodiment concerns the pharmaceutical composition comprising liposomes having GPL or SPL with at least one C₁₅ acyl chain. Yet another particular embodiment concerns the pharmaceutical composition comprising GPLs having at least one of C₁₄, C₁₅, C₁₆, and C₁₈ acyl chains. Still another particular embodiment concerns the pharmaceutical composition comprising liposomes having SPL with a C₁₆ acyl chain. Additional embodiments concern the pharmaceutical composition comprising a combination of any of the above liposomes.

In some embodiments at least one C₁₂-C₁₈ or C₁₂-C₁₆ hydrophobic chain is saturated. In further embodiments both C₁₂-C₁₈ and C₁₂-C₁₆ hydrophobic chains are saturated.

In one embodiment said C₁₂-C₁₈ or C₁₂-C₁₆ hydrophobic chains are unsaturated.

Non-limiting examples of the phospholipids which may be present in the liposome in accordance with the principles of the invention include 1,2-dimyristoyl-*sn*-glycero-3-phosphocholine (DMPC, *T_m* ~24°C); 1, 2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC, *T_m* 41.4°C); 1,2-dipentadecanoyl-*sn*-glycero-3-phosphocholine (C15, *T_m* 33.0°C); 1,2-distearoyl-

sn-glycero-3-phosphocholine (DSPC), T_m 55°C); and N-palmitoyl-D-*erythro*-sphingosylphosphorylcholine (D-*erythro* C16, T_m 41.0°C). T_m values of various PC-based lipids may be found in "Thermotropic Phase Transitions of Pure Lipids in Model Membranes and Their Modifications by Membrane Proteins", John R. Silvius, Lipid-Protein Interactions, John Wiley & Sons, Inc., New York, 1982, and also in the Lipid Thermotropic Phase Transition Data Base – LIPIDAT, and in Marsh (1990).

According to some embodiments, when using a mixture of two or more PLs, the mole ratio there between is designed such that the T_m of the combination provides a liposome in LD phase when the pharmaceutical composition is administered to the joint. In further embodiments, the mole ratio is chosen to provide a liposome having a phase transition temperature in the range of about 20°C to about 39°C.

In some embodiments, the liposome comprises DMPC. In further embodiments, the liposome consists essentially of DMPC. In still further embodiments, the at least one membrane of the liposome consists essentially of DMPC. In additional embodiments, the liposome consisting essentially of DMPC includes a tonicity agent having a concentration inside the liposome which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments, the liposome consisting essentially of DMPC includes a polyol having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further embodiments, the liposome consisting essentially of DMPC includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

In some embodiments, the pharmaceutical composition comprises a liposome comprising a combination of DMPC and an additional PC. In some embodiments, the pharmaceutical composition comprises a liposome comprising a combination of DMPC and an SPM.

In some embodiments, the mole percent of DMPC in the liposome membrane ranges from about 5% to about 100%. In further embodiments, the mole percent of DMPC in the liposome membrane ranges from about 5% to about 80%. In further embodiments, the mole percent of DMPC in the liposome membrane ranges from about 10% to about 75%, from about 15% to about 70%, from about 20% to about 65%, from about 25% to about 60%, from about 30% to about 55%, from about 35% to about 50%, from about 5% to about 15%, from about 20% to about 30%, from about 5% to about 30%, from about 40% to about 50%, or from about

70% to about 80%. Each possibility represents a separate embodiment of the invention. In some exemplary embodiments, the mole percent of DMPC in the liposome membrane is about 10%. In other exemplary embodiments, the mole percent of DMPC in the liposome membrane is about 25%. In further exemplary embodiments, the mole percent of DMPC in the liposome membrane is about 45%. In additional exemplary embodiments, the mole percent of DMPC in the liposome membrane is about 75%

In some embodiments, the liposome comprises a combination of DMPC and DPPC. In further embodiments, the liposome consists essentially of DMPC and DPPC. In still further embodiments, the at least one membrane of the liposome consists essentially of DMPC and DPPC. In additional embodiments, the liposome consisting essentially of DMPC and DPPC includes a tonicity agent having a concentration inside the liposome which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments, the liposome consisting essentially of DMPC and DPPC includes a polyol having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further embodiments, the liposome consisting essentially of DMPC and DPPC includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

In some embodiments, the mole percent ratio of DMPC to DPPC is in the range of about 25:75 to about 70:30. In further embodiments, the mole percent ratio of DMPC to DPPC is in the range of about 30:70 to about 65:25, from about 35:65 to about 60:30, or from about 40:60 to about 55:45. Each possibility represents a separate embodiment of the invention. In certain embodiments, the mole percent ratio of DMPC to DPPC is about 45:55. In additional embodiments, the mole percent ratio of DMPC to DPPC is about 25:75.

In some embodiments, the phase transition temperature of the liposome comprising a combination of DMPC and DPPC ranges between about 33 °C to about 37 °C.

In some embodiments, the liposome comprises a combination of DMPC and C15. In further embodiments, the liposome consists essentially of DMPC and C15. In still further embodiments, the at least one membrane of the liposome consists essentially of DMPC and C15. In additional embodiments, the liposome consisting essentially of DMPC and C15 includes a tonicity agent having a concentration inside the liposome which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments,

the liposome consisting essentially of DMPC and C15 includes a polyol having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further embodiments, the liposome consisting essentially of DMPC and C15 includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

In some embodiments, the mole percent ratio of DMPC to C15 is in the range of about 15:85 to about 55:45. In further embodiments, the mole percent ratio of DMPC to C15 is in the range of about 25:75 to about 45:55. In certain embodiments, the mole percent ratio of DMPC to C15 is about 45:55. In additional embodiments, the mole percent ratio of DMPC to C15 is about 25:75.

In some embodiments, the phase transition temperature of the liposome comprising a combination of DMPC and C15 ranges between about 29 °C to about 31 °C.

In some embodiments, the at least one membrane comprises DMPC and DSPC. In further embodiments, the liposome consists essentially of DMPC and DSPC. In still further embodiments, the at least one membrane of the liposome consists essentially of DMPC and DSPC. In additional embodiments, the liposome consisting essentially of DMPC and DSPC includes a tonicity agent having a concentration inside the liposome which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments, the liposome consisting essentially of DMPC and DSPC includes a polyol having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further embodiments, the liposome consisting essentially of DMPC and DSPC includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

In some embodiments, the mole percent ratio of DMPC to DSPC is about 75:25.

In some embodiments, the phase transition temperature of the liposome comprising a combination of DMPC and DSPC is about 27 °C.

In some embodiments, the liposome comprises a combination of DMPC and *D-erythro* C16. In further embodiments, the liposome consists essentially of DMPC and *D-erythro* C16. In still further embodiments, the at least one membrane of the liposome consists essentially of DMPC and *D-erythro* C16. In additional embodiments, the liposome consisting essentially of DMPC and *D-erythro* C16 includes a tonicity agent having a concentration inside the liposome

which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments, the liposome consisting essentially of DMPC and *D-erythro* C16 includes a polyol having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further
5 embodiments, the liposome consisting essentially of DMPC and *D-erythro* C16 includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

In some embodiments, the mole percent ratio of DMPC to *D-erythro* C16 is in the range of about 5:95 to about 50:50. In further embodiments, the mole percent ratio of DMPC to *D-erythro* C16 is in the range of about 10:90 to about 45:55, from about 10:90 to about 40:60, from
10 about 10:90 to about 35:65, from about 10:90 to about 30:70, or from about 10:90 to about 25:75. Each possibility represents a separate embodiment of the invention. In some embodiments, the mole percent ratio of DMPC to *D-erythro* C16 is in the range of about 5:95 to about 50:50. In some exemplary embodiments, the mole percent ratio of DMPC to *D-erythro*
15 C16 is about 10:90. In other exemplary embodiments, the mole percent ratio of DMPC to *D-erythro* C16 is about 25:75.

In some embodiments, the phase transition temperature of the liposome comprising a combination of DMPC and *D-erythro* C16 ranges between about 27 °C and 32 °C.

In some embodiments, the liposome comprises C15. In further embodiments, the
20 liposome consists essentially of C15. In still further embodiments, the at least one membrane of the liposome consists essentially of C15. In additional embodiments, the liposome consisting essentially of C15 includes a tonicity agent having a concentration inside the liposome which is essentially the same as the concentration of the tonicity agent in the medium outside the liposome. In further embodiments, the liposome consisting essentially of C15 includes a polyol
25 having a concentration inside the liposome which is essentially the same as the concentration of the polyol in the medium outside the liposome. In still further embodiments, the liposome consisting essentially of C15 includes mannitol having a concentration inside the liposome which is essentially the same as the concentration of mannitol in the medium outside the liposome.

30 The total PL concentration in the pharmaceutical composition according to some embodiments of the invention ranges from about 20 mM to about 500 mM. In further embodiments, the concentration ranges from about 50 mM to about 300 mM. In still further

embodiments, the concentration ranges from about 100 mM to about 200 mM. In yet further embodiments, the concentration ranges from about 130 mM to about 170 mM. In certain embodiments, the total PL concentration is about 150 mM.

In some embodiments, the total PL concentration ranges from about 10 mg/ml to about 500 mg/ml. In further embodiments, the concentration ranges from about 30 mg/ml to about 300 mg/ml. In still further embodiments, the concentration ranges from about 50 mg/ml to about 200 mg/ml. In certain embodiments, the total PL concentration is about 100 mg/ml.

In some embodiments, the phospholipids forming the liposomes are present in the pharmaceutical composition in a weight percent ranging from about 0.1% (w/w) to about 40% (w/w), from about 0.5% (w/w) to about 30% (w/w), from about 3% (w/w) to about 30% (w/w), or from about 1% (w/w) to about 20% (w/w) of the total weight of the pharmaceutical composition. In certain embodiments, the phospholipids forming the liposomes are present in the pharmaceutical composition in a weight percent of about 10% (w/w).

According to some embodiments, the liposomes suitable for use in the pharmaceutical composition of the present invention do not include in their bilayers a membrane active sterol, such as cholesterol. It is to be noted that the pharmaceutical composition of the present invention preferably does not contain propylene glycol. It should further be noted that the pharmaceutical composition of the present invention preferably does not contain dextran.

Additionally, it should be emphasized that the liposomes used in the pharmaceutical composition of the present invention are themselves used as an active ingredient and not as a carrier of a certain pharmaceutically active agent. As such and as mentioned hereinabove, the pharmaceutical compositions according to the principles of the present invention are essentially free of an additional pharmaceutically active agent. The term “essentially free of an additional pharmaceutically active agent”, as used herein, refers in some embodiments to the pharmaceutical composition including less than a therapeutically effective amount of the pharmaceutically active agent, which is known for use in joint lubrication, treatment of joint dysfunction, reduction of joint pain, irritation and/or wear, or any combination thereof. The term “known for use”, as used herein, refers in some embodiments, to pharmaceutically active agents approved for the indicated use at the time of the invention. In further embodiments, the term “known for use” refers to pharmaceutically active agents which will be approved for the indicated use in the future. In still further embodiments, the term “known for use” refers to

pharmaceutically active agents which are mentioned in scientific literature and/or patents as being suitable for the indicated use.

In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is a lubrication agent, such as, *inter alia*,
5 glycosaminoglycan or a pharmaceutically acceptable salt, ester or derivative thereof. In certain embodiments, said glycosaminoglycan is hyaluronic acid or hyaluronan-containing salt or ester. In certain embodiments, hyaluronic acid is not encapsulated within the liposome. Additionally or alternatively, the hyaluronic acid should not be dispersed in the fluid medium. In some currently preferred embodiments, the pharmaceutical composition is being essentially free of hyaluronic
10 acid, or a pharmaceutically acceptable salt or ester thereof. The term “essentially free”, as used in connection with hyaluronic acid, refers in some embodiments to the pharmaceutical composition including less than a therapeutically effective amount of hyaluronic acid or its salt or ester. In additional embodiments, the term “essentially free” refers to the pharmaceutical composition including less than a detectable amount of hyaluronic acid or its salt or ester.

15 In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is a lubrication agent selected from superficial zone protein (SZP), lubricin, proteoglycan 4 and analogs and derivatives thereof.

In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is an anti-inflammatory agent, such as xylitol,
20 betamethasone, prednisolone, piroxicam, aspirin, flurbiprofen, (+)-N-{4-[3-(4-fluorophenoxy)phenoxy]-2-cyclopenten-1-yl}-N-hydroxyurea salsalate, diflunisal, ibuprofen, fenoprofen, fenamate, ketoprofen, nabumetone, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, ketorolac, oxaprozin, celecoxib, meclofenamate, mefenamic acid, oxyphenbutazone, phenylbutazone, salicylates, or phytosphingosine type agents.

25 In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is an antiviral agent, such as acyclovir, nelfinavir, or virazole.

In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is an antibiotic, including antibiotics belonging to
30 the family of penicillines, cephalosporins, aminoglycosidics, macrolides, carbapenem and penem, beta-lactam monocyclic, inhibitors of beta-lactamases, and tetracyclins, polipeptidic antibiotics, chloramphenicol and derivatives, poly-etheric ionophores, and quinolones. Non-

limiting examples of such antibiotics include ampicillin, dapsone, chloramphenicol, neomycin, cefaclor, cefadroxil, cephalixin, cephradine, erythromycin, clindamycin, lincomycin, amoxicillin, ampicillin, bacampicillin, carbenicillin, dicloxacillin, cyclacillin, picloxacillin, hetacillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, ticarcillin, rifampin, 5 tetracycline, fusidic acid, lincomycin, novobiocine, and spectinomycin.

In some embodiments, the pharmaceutical composition of the present invention does not include a pharmaceutically active agent which is an anti-infective agent, such as benzalkonium chloride or chlorhexidine.

In some embodiments, the pharmaceutical composition of the present invention does not 10 include a pharmaceutically active agent which is a steroid. The term "steroid", as used herein, refers to naturally occurring steroids and their derivatives as well as synthetic or semi-synthetic steroid analogues having steroid-like activity. The steroid can be a glucocorticoid or corticosteroid. Examples of specific natural and synthetic steroids include, but are not limited to: aldosterone, beclomethasone, betamethasone, budesonide, cloprednol, cortisone, cortivazol, 15 deoxycortone, desonide, desoximetasone, dexamethasone, difluorocortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, halcinonide, hydrocortisone, icomethasone, meprednisone, methylprednisolone, paramethasone, prednisolone, prednisone, tixocortol or triamcinolone, and their respective pharmaceutically acceptable salts or derivatives.

20 According to some embodiments, the phospholipids are used in the pharmaceutical composition of the present invention as a sole active ingredient.

According to some embodiments, the pharmaceutical composition consists essentially of the non-ionic tonicity agent comprising a polyol and the liposomes, as described herein. In some 25 embodiments, the term "consisting essentially of" refers to a composition whose only active ingredient is the indicated active ingredient (i.e., liposomes), however, other compounds may be included which are for stabilizing, preserving, or controlling osmolarity, viscosity and/or pH of the formulation, but are not involved directly in the therapeutic effect of the liposomes and/or phospholipids. In some embodiments, the term "consisting" refers to a composition, which contains the liposomes, the tonicity agent and a pharmaceutically acceptable vehicle or excipient.

30 The pharmaceutical compositions according to the various embodiments of the invention can be sterilized and if desired mixed with auxiliary agents, e.g., preservatives, stabilizers,

wetting agents, synthetic emulsifiers, additional salts for influencing osmotic pressure, coloring, and/or aromatic substances and the like which do not deleteriously react with the liposomes.

The GPL, SPL or their combinations form liposomes, preferably liposomes with a mean diameter greater than about 0.3 μm , greater than about 0.5 μm , greater than about 0.8 μm , or
5 greater than about 1 μm . The mean diameter of the liposomes can be less than about 10 μm , 8 μm , 7 μm , 6 μm or 5 μm . Each possibility represents a separate embodiment of the invention. According to some embodiments, the liposomes have a mean diameter in the range of between about 0.3 μm and 10 μm . According to further embodiments, the liposomes have a mean diameter in the range of between about 0.5 μm and 9 μm . According to still further
10 embodiments, the liposomes have a mean diameter in the range of between about 1 μm and 8 μm . According to yet further embodiments, the liposomes have a mean diameter in the range of between about 3 μm and 5 μm .

The terms "mean diameter" and "mean particle size" are used herein interchangeably, referring, in some embodiments to the mean diameter of a liposome derived from particle size
15 distribution based on a number distribution model. In some embodiments, said terms refer to the mean diameter of a liposome derived from particle size distribution based on a volume distribution model. In additional embodiments, said terms refer to the mean diameter of a liposome derived from particle size distribution based on a surface area distribution model. Particle size distribution can be determined, *inter alia*, by laser light diffraction and/or by
20 Coulter Counter method.

The liposomes may be a single-membrane liposome or may be, according to some embodiments, multilamellar vesicles (MLV) liposomes. According to other embodiments the liposomes may also be large multivesicular vesicles (LMVV) or dehydrated rehydrated vesicles (DRV) liposomes.

25 In some currently preferred embodiments, the liposomes are multilamellar vesicles (MLV). In certain such embodiments, the liposomes have more than one membrane.

According to one embodiment, the MLV are defined by a mean diameter in the range of between 0.3 μm and 10 μm . According to another embodiment, the MLV are defined by a mean diameter in the range of between 0.5 μm and 9 μm . According to still further embodiments, the
30 MLV are defined by a mean diameter in the range of between about 1 μm and 8 μm . According

to yet further embodiments, the MLV are defined by a mean diameter in the range of between about 3 μm and 5 μm

In certain embodiments, the pharmaceutical composition comprises a polyol and MLV liposomes, which membranes consist essentially of DMPC and DPPC. The polyol can be selected from mannitol and glycerol. In a further embodiment, the pharmaceutical composition comprises mannitol and MLV liposomes, which membranes consist essentially of DMPC and DPPC. In an additional embodiment, the concentration of mannitol ranges between about 1 to about 70 mg/ml. In yet another embodiment, the pharmaceutical composition has osmolality in the range from about 200 to about 600 mOsm. In still another embodiment, the weight ratio between the liposomes and mannitol ranges from about 6:1 to about 2:1.

In some embodiments, the pharmaceutical composition comprises mannitol and MLV liposomes which membranes consist essentially of DMPC and DPPC. In some embodiments, DMPC is present in the pharmaceutical composition in a weight percent ranging from about 20% (w/w) to about 40% (w/w) of the dry weight of the pharmaceutical composition. In a certain embodiment, DMPC is present in the pharmaceutical composition in a weight percent of about 30% (w/w). In some embodiments, DPPC is present in the pharmaceutical composition in a weight percent ranging from about 30% (w/w) to about 60% (w/w) of the dry weight of the pharmaceutical composition. In a certain embodiment, DPPC is present in the pharmaceutical composition in a weight percent of about 40% (w/w). In some embodiments, mannitol is present in the pharmaceutical composition in a weight percent ranging from about 20% (w/w) to about 40% (w/w) of the dry weight of the pharmaceutical composition. In a certain embodiment, mannitol is present in the pharmaceutical composition in a weight percent of about 30% (w/w).

In some embodiments, the pharmaceutical composition comprising mannitol and liposomes which membranes consist essentially of DMPC and DPPC, further comprises histidine buffer as a fluid medium. In further embodiments, DMPC is present in the pharmaceutical composition in a weight percent ranging from about 1% (w/w) to about 10% (w/w) of the total weight of the pharmaceutical composition. In a certain embodiment, DMPC is present in the pharmaceutical composition in a weight percent of about 4% (w/w). In some embodiments, DPPC is present in the pharmaceutical composition in a weight percent ranging from about 2% (w/w) to about 12% (w/w) of the total weight of the pharmaceutical composition. In a certain embodiment, DPPC is present in the pharmaceutical composition in a weight percent of about 5% (w/w). In some embodiments, mannitol is present in the pharmaceutical composition in a

weight percent ranging from about 1% (w/w) to about 7% (w/w) of the total weight of the pharmaceutical composition. In a certain embodiment, mannitol is present in the pharmaceutical composition in a weight percent of about 4% (w/w).

The pharmaceutical composition according to various embodiments of the invention can be used for the preparation of a replacement of naturally-occurring cartilage PLs, namely as a joint lubricant and/or wear reducer.

It is noted that the temperature of joints in patients afflicted with reduced joint lubrication or with joint wear, such as osteoarthritis varies as the disease proceeds [Hollander, J. L.; Moore, R., Studies in osteoarthritis using Intra-Articular Temperature Response to Injection of Hydrocortisone. *Ann. Rheum. Dis.* **1956**, 15, (4), 320-326]. In fact, this temperature change was used as a clinical tool for assessing osteoarthritis inflammation [Thomas, D.; Ansell, B. M.; Smith, D. S.; Isaacs, R. J., Knee Joint Temperature Measurement using a Differential Thermistor Thermometer. *Rheumatology* **1980**, 19, (1), 8-13]. In hand joints of osteoarthritis patients temperature was shown to vary from ~28 to ~33°C [Varju, G.; Pieper, C. F.; Renner, J. B.; Kraus, V. B., Assessment of hand osteoarthritis: correlation between thermographic and radiographic methods. *Rheumatology* **2004**, 43, 915-919], while the temperature of healthy Temporomandibular joint (TMJ) varies from ~35 to 37°C [Akerman, S.; Kopp, S., Intra-articular and skin surface temperature of human temporomandibular joint. *Scand. J. Dent. Res.* **1987**, 95, (6), 493-498].

Thus, in accordance with the principles of the invention it is essential and in fact a prerequisite that the PLs or the mixture thereof be in a LD phase, *in situ*, at the joint region to be lubricated therewith. In some embodiments, the liposomes have an offset temperature (upper limit) of the SO to LD phase transition which is not higher than 15°C from the temperature *in situ*, i.e. in the joint, within the range of about 20°C to about 39°C. In accordance with the principles of the invention the liposomes are formed from GPL, SPL or their combination, and the SO to LD phase transition temperature described above thus concerns liposomes which are formed from GPL, SPL and combinations thereof, thus providing a liposome in which the PLs or their mixture are in LD phase.

In certain embodiments, the non-ionic tonicity agent comprising polyol does not affect the phase transition temperature of the liposomes. In further embodiments, the phase transition temperature of the liposomes combined with the non-ionic tonicity agent comprising polyol differs from the phase transition temperature of the liposomes alone by no more than about 10%.

In still further embodiments, the phase transition temperature of the liposomes combined with the non-ionic tonicity agent comprising polyol differs from the phase transition temperature of the liposomes alone by no more than about 5%.

The pharmaceutical composition of the invention may be used to treat, alleviate, retard, prevent, manage or cure any articular disorder or symptoms arising therefrom which is associated with joint dysfunction. The term "articular disorder", as used herein, should be held to mean any affliction (congenital, autoimmune or otherwise), injury or disease of the articular region which causes degeneration, pain, reduction in mobility, inflammation, irritation, or physiological disruption and dysfunction of joints. The disorder may be associated with reduced joint secretion and lubrication as well as from complications of knee and hip replacement.

The joint in accordance with the principles of the invention may be any one of the knee, hip, ankle, shoulder, elbow, tarsal, carpal, interphalangeal and intervertebral. Each possibility represents a separate embodiment of the invention. In certain embodiments, said joint is a knee joint.

Specific articular disorders include, but are not limited to, deficiencies of joint secretion and/or lubrication arising from arthritis, including conditions of joint erosion in rheumatoid arthritis, osteoarthritis, osteoarthritis in rheumatoid arthritis patients, traumatic joint injury (including sports injury), locked joint (such as in temporomandibular joint (TMJ)), status post arthrocentesis, arthroscopic surgery, open joint surgery, joint (e.g. knee or hip replacement) in mammals, preferably humans. A preferred disorder to be treated or prevented by use of the pharmaceutical composition of the invention is osteoarthritis.

In certain embodiments, the pharmaceutical composition is for the reduction of knee joint pain in osteoarthritis patients.

The pharmaceutical composition of the present invention could be used as a prophylactic measure to prevent future damage or degeneration. For example, the pharmaceutical composition could be administered intra-articularly to athletes intermittently throughout their career to minimize the risk of stress related injury or cartilage degeneration.

The pharmaceutical composition of the present invention may be administered exclusive of, or as an adjunct to, anti-inflammatory agents, analgesic agents, muscle relaxants, anti-depressants, or agents that promote joint lubrication commonly used to treat disorders associated with joint stiffness, such as arthritis. A combined therapeutic approach is beneficial in reducing side effects associated with agents, such as non-steroidal, anti-inflammatory drugs (NSAIDs),

commonly used to prevent, manage, or treat disorders such as osteoarthritis associated with reduced joint lubrication. In addition to enhancing safety, a combined therapeutic approach may also be advantageous in increasing efficacy of treatment.

In some embodiments, the pharmaceutical composition is in a form suitable for parenteral administration. The parenteral administration of the pharmaceutical composition of the invention into an articular cavity of a patient can be performed by a method chosen from the group consisting of intra-articular injection, arthroscopic administration or surgical administration. Accordingly, in some embodiments, the pharmaceutical composition is formulated in a form suitable for administration by a route selected from intra-articular injection, arthroscopic administration or by surgical administration. One of the beneficial features of the disclosed pharmaceutical composition is the presence of the tonicity agent, which adjusts the osmolality of the liposomal composition to a physiological value, thereby reducing the side effects associated with the intra-articular administration.

The pharmaceutical composition according to the various embodiments of the invention may be administered in a dose of from about 0.5 ml to about 10 ml. In further embodiments, the pharmaceutical composition is administered in a dose of from about 1 ml to about 6 ml. In certain embodiments, the pharmaceutical composition is administered in a dose of about 3 ml.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 20 mg to about 350 mg mannitol. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 40 mg to about 250 mg mannitol. In a certain embodiment, one dosage unit of the pharmaceutical composition comprises about 120 mg mannitol. In another embodiment, one dosage unit of the pharmaceutical composition comprises about 40 mg mannitol. In additional embodiment, one dosage unit of the pharmaceutical composition comprises about 250 mg mannitol.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 50 mg to about 1000 mg phospholipids. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 100 mg to about 800 mg phospholipids. In a certain embodiment, one dosage unit of the pharmaceutical composition comprises about 300 mg phospholipids. In another certain embodiment, one dosage unit of the pharmaceutical composition comprises about 100 mg phospholipids. In additional embodiment, one dosage unit of the pharmaceutical composition comprises about 600 mg phospholipids.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 30 mg to about 550 mg DPPC. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 50 mg to about 500 mg DPPC. In a certain embodiment, one dosage unit of the pharmaceutical composition comprises about 180 mg DPPC.

5 In another embodiment, one dosage unit of the pharmaceutical composition comprises about 60 mg DPPC. In additional embodiment, one dosage unit of the pharmaceutical composition comprises about 365 mg DPPC.

In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 20 mg to about 450 mg DMPC. In some embodiments, one dosage unit of the pharmaceutical composition comprises from about 40 mg to about 300 mg DMPC. In a certain
10 embodiment, one dosage unit of the pharmaceutical composition comprises about 140 mg DPPC. In another embodiment, one dosage unit of the pharmaceutical composition comprises about 45 mg DPPC. In a certain embodiment, one dosage unit of the pharmaceutical composition comprises about 275 mg DPPC.

15 The pharmaceutical composition can be portioned in vials or in single injections or any other convenient way for practical use.

Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include mammals, such as, but not limited to, humans and other primates.

20 Throughout the description and claims of this specification, the singular forms "a" "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to "a PL" is a reference to one or more PLs and "a liposome" refers to one or more liposomes. Throughout the description and claims of this specification, the plural forms of words include singular references as well, unless the context clearly dictates otherwise. It
25 should be noted that the term "and" or the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

Yet, throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", mean "including but not limited to", and are not intended to (and do not) exclude other moieties,
30 additives, components, integers or steps.

As used herein, the term "about", when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of +/-10%, more

preferably $\pm 5\%$, even more preferably $\pm 1\%$, and still more preferably $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods.

The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

EXAMPLES

Materials and Methods

Materials

1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC 14:0, Cat: 556200), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC 16:0, Cat: 556300) were obtained from Lipoid (Ludwigshafen, Germany). 1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC 18:0, Cat: 850365P), 1,2-dipentadecanoyl-sn-Glycero-3-Phosphocholine (C15 (also abbreviated herein as PC (15:0)), Cat: 850350P) were obtained from Avanti Polar Lipids (Alabaster, AL, USA). N-Palmitoyl-D-erythro-Sphingosylphosphorylcholine (Palmitoyl Sphingomyelin, *D-erythro* C16 (also abbreviated herein as C16 SPM), Cat: 16608050) was obtained from Bio-Lab Ltd. (Jerusalem, Israel)

Highly pure water (resistance of 18.2 megaOhm) was obtained using the WaterPro PS HPLC/Ultrafilter Hybrid System (Labconco, Kansas City, MO). HPLC-grade ethanol was obtained from BioLab Ltd, Jerusalem, Israel. L-histidine mono hydrochloride monohydrate, Sodium hydroxide (NaOH) and D-Mannitol were all obtained from Merck (Darmstadt, Germany). Glycerol was obtained from Merck, cat no. 1.04093. Sodium chloride was obtained from J. T. Baker, cat no. 4058-02

Methods

Preparation of hypotonic compositions comprising MLV liposomes

A mixture of the desired phospholipids was dissolved in 2.5ml ethanol to a concentration of 180mM. This solution was stirred by vortex and placed in water bath (60°C) for ~20 minutes. Stirring was repeated for several times until the phospholipids were fully dissolved. The ethanolic solution was transferred into 10ml warm 10mM or 7.5mM histidine buffer (pH 6.5)

mixed vigorously by vortex for 2 min in order to hydrate the lipids and form a dispersion of the desired MLV.

Ethanol was removed by 5 cycles of centrifugation and cold buffer replacement at 4°C. For liposomal systems consisting of PCs centrifuge was done at 3000 rpm, for 40 minutes in the 1st cycle and 30 minutes at 4000rpm in subsequent cycles. For liposomal systems comprising SPL centrifuge was done at 4000 rpm, for 50 minutes twice with an overnight standby in-between in the 1st cycle, and twice for 40 minutes at 4000rpm in cycles 2 and 3. Cycles 4 and 5 were done for 60min at 4000 rpm. Monitoring on ethanol removal was done by osmolality measurements. After every cold buffer replacement, the pellets were resuspended using a sterile pipette to loosen the sticky pellet, then the tubes are closed tightly and vortexed for 2 minutes. The centrifugation process and solution replacement were repeated until the osmolality in the mixture was less than 50mOsm. The osmotic pressure of HB (10mM, 7.5mM) was measured and was found to be 26 and 19 mOsm, respectively. MLV were stored at 2-8°C until analysis.

Preparation of isotonic compositions comprising MLV liposomes and a tonicity agent

The liposomes were prepared as described hereinabove. The ethanolic solution of the liposomes was transferred into 10ml warm 13.5 mM histidine buffer (pH 6.5) comprising a tonicity agent selected from mannitol, glycerol and sodium chloride and mixed vigorously by vortex for 2 min in order to hydrate the lipids and form a dispersion of the desired MLV.

Concentrations of the tonicity agents in the histidine buffer were as follows: Glycerol – 235 mM; Mannitol – 234 mM; and NaCl – 131 mM.

The centrifugation process and solution replacement were repeated until the osmolality in the mixture was about 300mOsm. The compositions were stored at 2-8°C until analysis.

MLV liposomes characterization

Phospholipid concentration was determined using a modified Bartlett method [Barenholz, Y. and S. Amselem, *Quality control assays in the development and clinical use of liposome-based formulations*. Liposome technology, 1993. 1: p. 527-616]. Liposome size distribution was determined by laser diffraction particle size analyzer (LS13320 Beckman Coulter), which enables measuring particle size in the range of 40nm to 2mm. Coulter Counter method (which is based on measuring the changes in electrical conductance as particles suspended in a conductive fluid pass through a small orifice) was also used for size distribution determination.

The cartilage-on-cartilage *ex vivo* model for the lubrication efficiency evaluation

Normal articular cartilage from donors (Ages: male 70 yrs and female 68, 72, 81, 87, 98 yrs.) were obtained from operations of femoral head fractures at the Hadassah Medical Center, Jerusalem. Tissue was frozen at -20° C until analyzed.

5 Synovial fluid was pooled from 8 donors at the Hadassah Medical Center, Jerusalem.

Reagents used for the preparation of cartilage specimens included Superglue (cyanoacrylate adhesive, 3g), NaCl (Bio Lab LTD, Israel, 19030291 Cat no: 19030291 Lot. no: 57747), and ethanol (Frutarom, Israel, Cat no: 5551640 Lot. no: 26141007).

10 Samples were prepared in the laboratory of Cartilage and Joints Diseases, the Department of Biomedical Engineering Technion, IIT, Haifa, Israel. Tests were performed at the Shamban & Microsystems Tribology Laboratories, the Department of Mechanical Engineering Technion, IIT, Haifa, Israel. The in-house apparatus for friction measurements was equipped with load cell with a strain gauge measuring system (HBM Z8, Germany) and LabView software (National
15 Instruments, USA).

The apparatus was set up as follows. The cartilage plugs were prepared and fixed. From every cartilage, 10-20 plugs, of either 4 mm or 8 mm in diameter were prepared. These plugs were randomly assigned to the various tested formulations. The 8 mm plugs were mounted in the apparatus on the fixed holder and submerged in a solution containing 2 ml of synovial fluid (SF)
20 and the tested solution in a 1:1 ratio (v/v). The 4 mm plugs were fixed on the upper piston.

Measurements: The friction test was performed with multiple repetitions in the presence of the different tested samples. For every measurement, the upper plug was positioned over the bottom plug, and following several seconds dwelling interval, the friction coefficient was measured. For any given pair of plugs, not less than 10 independent measurements were
25 performed, with the plugs being rotated before each subsequent test for providing similar conditions in all repetitions.

Static friction coefficient was determined under specific tribological conditions of applied load, sliding velocity, dwell time and temperature, as shown in Table 1:

Table 1: Cartilage-on-cartilage model experimental conditions:

Normal load	30 N
Sliding velocity	1 mm s ⁻¹
Dwell time (duration of loading before sliding start)	5 s
Sliding distance	5 mm
Lubricant temperature	32 to 34 °C

Differential scanning calorimetric (DSC) measurements

For determination of the T_m of the different liposomal systems, samples were scanned using MicroCal™ VP-DSC GE Healthcare Life Sciences (Uppsala, Sweden, now owned by Malvern UK). Samples of MLV in HB and of a pharmaceutical composition comprising liposomes and mannitol, at a concentration of about 20mM phospholipid, with HB or HB with mannitol in the reference cell, were scanned in the range between 10° and 75 °C, at the heating rate of 1°C/min. Each sample studied was scanned three times at the same rate – increasing the temperature from 10°C to 75°C (scan 1), decreasing the temperature from 75°C to 10°C (scan 2) and again increasing the temperature from 10°C to 75°C (scan 3). Processing of the calorimetric data was done by the Origin® 7.0 software. T_{on} and T_{off} of the main phase transition were determined by extrapolating a straight line to define the temperature range of the main phase transition. For system F1 additional analysis by fitting Model: MN2State was done due to a broad "shoulder" in peak 2.

Example 1 – Effect of the tonicity agent on the lubrication properties of the liposomal pharmaceutical composition

Cartilage lubrication by the pharmaceutical composition comprising a tonicity agent and liposome was evaluated using cartilage-on-cartilage *ex vivo* model. The cartilage-on-cartilage *ex vivo* model offers an experimental system to test the relative effect of bio-lubricant preparations on the static friction coefficient. This type of measurement may be indicative of the ability of different lubricants to reduce cartilage friction coefficient. The cartilage-on-cartilage *ex vivo* model utilizes an apparatus where two fixed human cartilage plugs are allowed to slide one over the other while submerged in different lubricants solutions. The apparatus enables measurement of static friction between the two cartilage specimens [Merkher Y et al. "A rational human joint friction test using a human cartilage-on-cartilage." Tribology Letters (2006): 29-36]. This model has been used in the past in order to compare the friction coefficient of different liposomal

compositions [Sivan S et al. "Liposomes act as effective biolubricants for friction reduction in human synovial joints." *Langmuir* (2010): 1107-16].

The present experiment was designed to determine the relative lubrication properties of liposomal formulations comprising a tonicity agent, as reflected by the static friction coefficient measurements and to compare them to the hypotonic liposomal formulation. Table 2 presents the pharmaceutical compositions, which were tested. The chosen liposomal combination was DMPC/DPPC with a mole percent ratio of 45:55.

Table 2: Hypotonic and isotonic liposomal compositions

Formulation #	Phospholipid (mole percent ratio)	Tonicity agent	Fluid medium
1	DMPC/DPPC (45 : 55)	-	Histidine Buffer
2	DMPC/DPPC (45 : 55)	Glycerol	Histidine Buffer
3	DMPC/DPPC (45 : 55)	Mannitol	Histidine Buffer
4	DMPC/DPPC (45 : 55)	NaCl	Histidine Buffer

The liposomal compositions comprised 183 mg of DPPC and 136 mg of DMPC dispersed in 3 ml of 10mM Histidine buffer (HB) pH 6.5. The liposomal compositions comprising the 10 mM Histidine buffer had an osmolality of about 50 mOsm (Table 3). Accordingly, in order to increase the osmolality to the isotonic level of about 300 mOsm, the concentration of the tonicity agent should be adjusted to provide about 250 mM solute.

Mannitol was added in the amount of 120 mg (4% wt. or 40 mg/ml) to form an isotonic composition. Glycerol was added in the amount of 61 mg (2% wt. or 20 mg/ml). Sodium chloride was added in the amount of 21 mg.

Table 3 summarizes the physicochemical properties of the different liposomal compositions. Liposomal compositions were prepared with three different tonicity agents, each has equal contribution to the overall osmolality of the preparation. The isotonicity of these preparations was about 300 mOsm. A comparison between ionic (NaCl) and non-ionic (mannitol and glycerol) tonicity agents was performed. A hypotonic liposomal composition without a tonicity agent (less than 50 mOsm) was also tested. The effect of the tonicity agent on the lubrication ability of the liposomal composition was assessed using the cartilage-on-cartilage model setup, as described in *Materials and Methods*.

Table 3: Physicochemical properties of the liposomal compositions.

		Isotonic formulations		
	Buffer	Mannitol	Glycerol	NaCl
pH	6.6	6.4	6.4	6.4
Osmolality (mOsm)	49	307	299	289
Particle size by volume (μm)	5.8	4.4	3.8	4.5
Particle size by surface area (μm)	3.4	2.8	2.9	3.2
Particle size by number (μm)	1.3	1.5	1.7	1.8
Assay DMPC (mM)	66.4	67.5	70.2	69.6
Assay DPPC (mM)	81.7	82.1	84.7	83.3
Phospholipid concentration (mM)	148	150	155	153
Mole percent ratio DMPC/DPPC	55.2/44.8	45.1/54.9	45.3/54.7	45.5/54.5
Lyso-myristoyl phosphatidylcholine (%)	NMT* 0.5	ND**	ND	ND
Lyso-palmitoyl phosphatidylcholine (%)	NMT 0.5	ND	ND	ND
Myristic acid (%)	0.27	ND	ND	ND
Palmitic Acid (%)	0.27	0.06	0.04	ND
Total impurities	LT*** 0.2	0.06	0.04	ND

*NMT - Not more than

**ND - Not detected

***LT - Less than

5

Table 4 presents preliminary results of average static friction coefficients obtained in the experiment. The precision of measurements repetitions is similar among all tested formulations, as reflected by the relative SD.

Table 4: Lubrication properties of the liposomal compositions.

Formulation	Buffer	Glycerol	Mannitol	NaCl
Number of repetitions	53	55	56	50
Av. Static Friction Coefficient	0.093	0.075	0.064	0.098
S.D.	0.025	0.020	0.022	0.026

10

Comparison of formulations revealed that the preparation containing mannitol exhibited the lowest static friction coefficient as compared with other isotonic formulations. The lowest static friction coefficient indicates that the mannitol formulation possesses higher lubrication properties. It was surprisingly found that the static friction coefficient obtained when using the mannitol formulation was about 30% lower than when using the hypotonic liposomal composition without a tonicity agent. The glycerol formulation also provided better lubrication (about 20% lower average static friction coefficient as compared to the hypotonic formulation).

15

In contrast, addition of the ionic tonicity to the liposomal composition agent did not enhance lubrication ability thereof.

Example 2 – Effect of the he tonicity agent on the thermotropic properties of the liposomal pharmaceutical compositions

The present experiment was designed to determine whether the addition of a tonicity agent affects the thermotropic behavior and thermodynamic parameters of the liposomal composition, including the range of the SO-LD phase transition ($T_{on} \rightarrow T_{off}$), T_p , T_m , $T_{1/2}$, and ΔH . T_{on} and T_{off} represent the temperature at which the SO-LD phase transition was initiated and ended during heating scans, T_p , and T_m represent the temperature at which the maximum change in the heat capacity during the pre-transition (T_p) and main transition (T_m) occurs, $T_{1/2}$ represent the temperature (width) range at half height of the endotherm representing the change of enthalpy during the SO-LD phase transition and ΔH is the area under the curve representing the total change in enthalpy during the SO-LD phase transition.

Two types of liposomal compositions were chosen, each one was tested with and without mannitol (as a tonicity agent). The tested liposomal compositions are presented in Table 5.

Table 5: Hypotonic and isotonic liposomal compositions

Phospholipid (mole percent ratio (where applicable))	Tonicity agent	Fluid medium
DMPC/DPPC (45 : 55)	-	Histidine Buffer
DMPC/DPPC (45 : 55)	Mannitol	Histidine Buffer
1,2-dipentadecanoyl- <i>sn</i> -glycero-3-phosphocholine (C15)	-	Histidine Buffer
1,2-dipentadecanoyl- <i>sn</i> -glycero-3-phosphocholine (C15)	Mannitol	Histidine Buffer

The DMPC/DPPC liposomal compositions comprised 183 mg of DPPC and 136 mg of DMPC dispersed in 3 ml of 10mM Histidine buffer (HB) pH 6.5. The C15 liposomal composition comprised 212 mg (70.6 mg/ml) phospholipid. Mannitol was added in the amount of 120 mg (4% wt.) to form isotonic compositions.

Table 6 summarizes the physicochemical properties of the different liposomal compositions.

Table 6: Physicochemical properties of the liposomal compositions.

Phospholipid	Tonicity agent	Total PCs (mM)	MLV osmolality (mOsm)	Size distribution by volume		
				Av. Mean (μm)	Median (μm)	S.D.
DMPC/DPPC	-	105	34	2.7	2.18	1.73
DMPC/DPPC	mannitol	91	288	4.24	2.70	4.61
C15	-	102.7	28	3.97	2.59	3.96
C15	mannitol	99.3	272	3.1	2.61	1.96

For determination of the thermotropic behavior and thermodynamic parameters ($T_{\text{on}} \rightarrow T_{\text{off}}$, T_m , $T_{1/2}$, ΔH) of the different systems, samples were scanned using MicroCalTM VP-DSC (GE Healthcare Life Sciences, Uppsala, Sweden). Processing of the calorimetric data was done by the Origin[®] 7.0 software. The way $T_{\text{on}} \rightarrow T_{\text{off}}$ range was determined is described in *Materials and Methods*.

Table 7 presents thermotropic characterization of the tested liposomal compositions assessed from the DSC scans

Table 7: Thermotropic characterization of the liposomal compositions.

Phospholipid	Tonicity agent	Thermotropic characterization									
		Peak 1 (pre-transition)					Peak2 (phase-transition)				
		T_{on} ($^{\circ}\text{C}$)	T_{off} ($^{\circ}\text{C}$)	T_p ($^{\circ}\text{C}$)	$T_{1/2}$ ($^{\circ}\text{C}$)	ΔH (Cal/mole)	T_{on} ($^{\circ}\text{C}$)	T_{off} ($^{\circ}\text{C}$)	T_m ($^{\circ}\text{C}$)	$T_{1/2}$ ($^{\circ}\text{C}$)	ΔH (Cal/mole)
DMPC/DPPC	-	17.8	24.7	21.0	2.2	1030.5	30.44	35.19	33.6	3.5	9782.1
DMPC/DPPC	mannitol	17.6	24.5	21.0	2.5	962.7	30.49	35.42	33.7	3.3	10707.7
C15	-	21.7	27.3	24.6	2.2	1316.9	33.03	35.16	34.3	1.3	6716.9
C15	mannitol	20.5	27.0	24.5	2.5	1009.1	32.66	35.29	34.4	1.5	6081.3

The results summarized in Table 7 and Figures 1 and 2 indicate lack of mannitol effect on the thermotropic behavior of DMPC/DPPC 45/55 mole ratio MLV and of 100 mole % C15 MLV.

Example 3 – Phase transition temperatures of the liposomal combinations

The present study was configured to assess the thermotropic behavior and thermodynamic parameters of various liposomal compositions and in particular to find liposomal combinations having phase transition temperatures in the range of 20 $^{\circ}\text{C}$ to 39 $^{\circ}\text{C}$. Since the addition of mannitol does not affect thermotropic behavior of the liposomes (as was shown in Example 2), the phase transition temperatures of the various liposomal compositions tested in the present study should be similar to the that of the corresponding isotonic compositions.

The tested liposomal compositions are presented in Table 8.

Table 8: Liposomal compositions

System	Phospholipid (mole %)					Buffer	Expected T _m
	DMPC	DPPC	DSPC	C15	D- erythro C16		
A1	0	100	-	-	-	HB	41°C
B1	10	90	-	-	-	HB	<41°C
C1	25	75	-	-	-	HB	<<41°C
D1	45	55	-	-	-	HB	~34°C
F1	75	-	25	-	-	HB	<<55°C
G1	45	-	-	55	-	HB	<<35°C
H1	25	-	-	75	-	HB	<35°C
A2	-	-	-	-	100	HB	~41°C
B2	10	-	-	-	90	HB	<41°C
C2	25	-	-	-	75	HB	<41°C
D2	75	-	-	-	25	HB	<<41°C
E2	90	-	-	-	10	HB	<<41°C
F2	100	-	-	-	-	HB	~24°C
G2	-	-	-	100	-	HB	~34°C

The different MLV systems were characterized for size distribution, osmolality and total

5 PC concentrations. The results are summarized in tables 9-12.

Table 9: Physicochemical properties of MLV of different DPPC: DMPC mixtures

System PC ratio (mole %)	Total PCs (mM)	MLV osmolality (mOsm)	Size distribution by volume		
			Av. Mean (μm)	Median (μm)	S.D.
A1 DPPC 100	93	31	3.12	2.4	2.38
B1 DMPC/DPPC 10/90	111	29	3.10	2.34	2.31
C1 DMPC/ 25/75	107	27	3.92	2.64	4.03
D1 DMPC/DPPC 45/55	105	34	2.7	2.18	1.73
F2 DMPC 100	136.5	32	2.93	1.87	3.02

Based on osmolality results described in this table, the ethanol level is below 0.1% for all MLV systems. Based on the Liposome/water partition coefficient, most of it is in the aqueous phase.

10 Table 10: Physicochemical properties of MLV of DSPC: DMPC mixture

System PC ratio (mole %)	Total PCs (mM)	MLVs osmolality (mOsm)	Size distribution by volume		
			Av. Mean (μm)	Median (μm)	S.D.
F1 DMPC/DSPC 75/25	69	50	3.72	3	2.77

Based on osmolality results described in this table the ethanol level is below 0.2%. Based on the Liposome/water partition coefficient, most of it is in the aqueous phase. This MLV represent a major lipid loss which occurred during the removal of the ethanol.

Table 11: Physicochemical properties of MLV of different C15:DMPC mixtures

System PC ratio (mole %)	Total PCs (mM)	MLVs osmolality (mOsm)	Size distribution by volume		
			Av. Mean (μm)	Median (μm)	S.D
G2 PC(15:0) 100	102.7	28	3.97	2.59	3.96
G1 DMPC/PC15 45/55	103	40	4.57	3.44	3.84
H1 DMPC/PC15 25/75	97	34	3.06	2.16	2.38

5

Based on osmolality results described in this table, the ethanol level is below 0.1% for all MLV systems. Based on the Liposome/water partition coefficient, most of it is in the aqueous phase.

Table 12: Physicochemical properties of MLV of different DMPC/D-erythro C16 mixtures

10

System PC ratio (mole %)	Total PCs (mM)	MLVs osmolality (mOsm)	Size distribution by volume		
			Av. Mean (μm)	Median (μm)	S.D
A2 D-erythro C16 100	53.9	20	4.04	2.66	4.38
B2 DMPC/ D-erythro C16 10/90	76.6	20	3.31	2.27	3.25
C2 DMPC/ D-erythro C16 25/75	85.7	21	3.37	2.31	3.18
D2 DMPC/ C16 D-erythro C16 75/25	90.4	24	2.67	2.05	1.83
E2 DMPC/ D-erythro C16 10/90	56.6	22	3.7	3.03	2.5
F2 DMPC 100	136.5	32	2.93	1.87	3.02

Based on osmolality results described in this table, the ethanol level is below 0.1% for all MLV systems. Based on the Liposome/water partition coefficient, most of it is in the aqueous phase.

15

The thermotropic behavior and thermodynamic parameters of the liposomal combinations were assessed as described in Example 2 and in *Materials and Methods*. Table 13 summarizes the thermotropic characterization results of the liposomal combinations tested and Figure 3

shows the SO-LD phase transition temperature range of MLV of different phospholipids mixtures assessed from the DSC scans.

Table 13: Thermotropic characterization of MLV of the different mixtures assessed from the DSC scans

PC ratio (mol %)	Thermotropic characterization									
	Peak 1 (pre-transition)					Peak2 (phase-transition)				
	T _{on} (°C)	T _{off} (°C)	T _p (°C)	T _{1/2} (°C)	ΔH (Cal/mole)	T _{on} (°C)	T _{off} (°C)	T _m (°C)	T _{1/2} (°C)	ΔH (Cal/mole)
DPPC: DMPC mixtures										
DPPC (100)	32.3	37.3	34.9	2.2	1983.5	40.44	42.45	41.8	1.3	7993.7
DMPC/DPPC (10/90)	28.3	33.8	30.8	2.9	1666.2	37.77	40.91	40.0	1.9	9982.4
DMPC/DPPC (25/75)	22.6	29.8	25.8	3.2	1429.3	34.24	38.23	37.4	2.8	10363.0
DMPC/DPPC (45/55)	17.8	24.7	21.0	2.2	1030.5	30.44	35.19	33.6	3.5	9782.1
DMPC (100)	11.4	16.4	14.0	1.0	683.7	23.24	25.24	24.4	1.1	5394.7
DSPC: DMPC mixture										
DMPC/DSPC (75/25)	11.4	17.4	14.2	4.0	369.5	24.67	34.6	27.1	2.7	10199.9
C15: DMPC mixtures										
C15 (100)	21.7	27.3	24.6	2.2	1316.9	33.03	35.16	34.3	1.3	6716.9
DMPC/C15 (45/55)	15.9	21.0	18.1	1.7	1059.7	28.03	30.28	29.4	1.3	7767.7
DMPC/C15 (25/75)	17.9	22.9	20.4	1.2	851.1	30.35	32.12	31.3	1.2	7107.5
D-erythro C16/DMPC mixtures										
SPM (100)	30.2	38.8	33.9	0.8	941.5	41.14	43.24	41.8	1.0	7967.0
D-erythro C16/DMPC (90/10)	32.5	36.0	33.8	0.7	200.2	38.36	41.91	39.7	2.2	7503.7
D-erythro C16/DMPC (75/25)	22.3	25.8	23.8	0.5	97.5	34.7	39.77	36.5	3.1	6758.1
D-erythro C16/DMPC (25/75)	13.9	19.1	16.6	2.9	126.9	30.91	36.19	32.1	3.2	7304.5
D-erythro C16/DMPC (10/90)	11.4	14.8	13.0	1.3	233.9	26.68	29.72	27.5	1.7	7592.0
DMPC (100)	11.4	16.4	14.0	1.0	683.7	23.24	25.24	24.4	1.1	5394.7

It can be seen that various liposomal combinations, including, for example, DMPC/DPPC (25/75), DMPC/DPPC (45/55), DMPC/DSPC (75/25), DMPC/C15 (45/55), DMPC/C15 (25/75), D-erythro C16/DMPC (75/25), D-erythro C16//DMPC (25/75), and D-erythro C16/DMPC

(10/90) have a phase transition temperature of the liposome membranes in the desired 20 °C to 39 °C temperature range.

Example 4 - Evaluation of the liposomal composition by a pin-on-disc cartilage abrasion test

5 Tribological conditions in the knee were simulated in vitro by a pin-on-disc test using porcine cartilage pins sliding against CoCrMo discs. The pin-on-disc tests were carried out on an OrthoPOD machine from Advanced Mechanical Technology Inc. (AMTI), Watertown, MA 02472-4800, USA. The machine was heated by a thermostat to ensure a temperature of 37 ± 3 °C inside the liquid. The cylindrical containers were filled with 20 mL of test liquid. The forces
10 applied by each individual holding arm were checked with the pin centered above the disc at 3, 10, 30, 50 and 100 N using a Mecmesin force gauge.

The cartilage pins were retrieved from pig shoulders. The joint capsule was opened using a scalpel to expose the cartilage surface. At least ten cylindrical pins were harvested by using a hollow punch with 5.0 mm inner diameter. Six pins from the same animal, with appropriate
15 length and the least surface inclination, were chosen for each pin-on-disc abrasion test.

Lubrication ability of the pharmaceutical composition of the invention was assessed by measuring subchondral bone mass loss and height loss following 12 hours of wear testing. Six cartilage pins were used for each test whereas three pins were removed after 6 hours and the other three pins were tested for additional 6 hours. Besides determining the weight and mass loss
20 of the pins, the cartilage surfaces were analyzed by an optical profiler before and after the test. The device used was S neox interferometry and confocal microscope (Sensofar, Spain). To determine the roughness parameters, more than 12 line profiles were extracted from the topographies after the form removal. For the illustration of the surface obliqueness, profiles were extracted from the 5X confocal measurements in north-south direction as positioning of the pins
25 was with the highest level facing towards south. For enhanced clarity, these profiles were smoothed and shifted using Kaleidagraph 4.0.

The liposome-based composition comprising mannitol (Formulation # 3 from Table 2) was tested in the wear test. This composition was compared to a protein containing liquid, containing 30 g/l of calf serum proteins, EDTA and NaN_3 , as used for hip simulator test (ISO
30 14242-1).

Results

Wear test

The Pin-on-Disc tests within protein containing liquid revealed wear of the cartilages. Average mass loss of the pins increased from 22 mg after 6 hours to 26 mg after 12 hours of testing. The increase in average height loss of the pins was more pronounced with 0.6 mm after 6 hours and 1.1 mm after 12 hours of wear. The extracted profiles (Figure 4) show that after 6 hours of wear, the cartilage surfaces had flattened. Some of the cartilage material was moved aside and formed an outer bulge which was only loosely attached to the initial pin. The actual mass loss was therefore underestimated as the weights were determined including the attached bulge. After 12 hours of wear, the three remaining pins showed areas where the cartilage had been worn through and where subchondral bone appeared (Figure 4 and Figures 5A, 5B).

The cartilage pins in the liposomal composition (Formulation #3) showed signs of abrasion after removal. Average mass loss of the pins was 14 mg after 6 hours of wear and remained at that level for the additional 6 hours of wear. The height loss was around 0.3 to 0.4 mm for the two time points. After 6 hours of wear, the cartilage surfaces had flattened (Figure 6 and Figures 7A, 7B) and cartilage material was forming a bulge around the center. After 12 hours of wear, the cartilage surfaces of the remaining pins were still intact and did not show areas with appearing subchondral bone (Figures 8A, 8B).

The cartilage pins in protein liquid showed the appearance of subchondral bone after 12 hours of wear testing unlike the pins in liposomal composition where cartilage remained intact throughout the test. Wear seemed to slow down in liposomal composition as no additional mass loss or height loss was observed between 6 and 12 hours

The wear results are further illustrated in Figures 9A (mass loss) and 9B (height loss). The comparison of the two liquids showed that the liposomal composition led to smaller mass and height loss of the cartilage pins.

Roughness measurements

The roughness parameters were determined from a series of extracted profiles based on the interferometry measurements with the DI 10X objective. The measurements were taken in the central part of the pin, well within the contact surface. Figures 10A and 10B show exemplary profiles after form removal of the underlying plane.

The selected roughness parameters Ra, Rk, Rpk and Rvk are shown in Figure 11. For the wear tests in the protein-based liquid, a highly significant increase of these parameters due to

wear could be observed ($p < 0.01$). For example, the average roughness R_a increased from $0.5 \pm 0.2 \mu\text{m}$ at $t = 0$ to $1.6 \pm 0.4 \mu\text{m}$ for the worn pins and the kernel roughness R_k from $1.4 \pm 0.5 \mu\text{m}$ to $4.5 \pm 1.1 \mu\text{m}$. For the wear test in the liposomal composition, a smaller but significant increase of the roughness parameters was observed with the exception of R_{pk} ($p > 0.2$). The
5 average roughness R_a increased from $0.4 \pm 0.2 \mu\text{m}$ to $0.8 \pm 0.3 \mu\text{m}$ and the kernel roughness R_k from $0.9 \pm 0.4 \mu\text{m}$ to $2.4 \pm 0.8 \mu\text{m}$.

It is appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather the scope of the present invention includes both combinations and sub-combinations of various features described
10 hereinabove as well as variations and modifications. Therefore, the invention is not to be constructed as restricted to the particularly described embodiments, and the scope and concept of the invention will be more readily understood by references to the claims, which follow.

CLAIMS:

1. A pharmaceutical composition comprising:
 - a non-ionic tonicity agent, comprising a polyol; and
 - liposomes comprising at least one membrane comprising at least one phospholipid (PL)
 - 5 selected from a glycerophospholipid (GPL), said GPL having two C₁₂-C₁₈ hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C₁₂-C₁₈ hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C;
 - wherein the pharmaceutical composition is essentially free of an additional
 - 10 pharmaceutically active agent,
 - the pharmaceutical composition being for use in the lubrication of a mammalian joint having a temperature which is above the phase transition temperature.
2. The composition according to claim 1, wherein the polyol is selected from mannitol and glycerol.
- 15 3. The composition according to claim 2, wherein the tonicity agent comprises mannitol.
4. The composition according to any one of claims 1 to 3, further comprising a fluid medium in which the liposomes are suspended.
5. The composition according to claim 4, wherein said fluid medium is selected from buffer and water.
- 20 6. The composition according to claim 5, wherein said buffer is selected from a histidine buffer and phosphate buffered saline.
7. The composition according to any one of claims 1 to 6, wherein polyol is present in the pharmaceutical composition in a weight percent ranging from about 0.05% (w/w) to about 10% (w/w).
- 25 8. The composition according to claim 7, wherein mannitol is present in the pharmaceutical composition in a weight percent ranging from about 0.1% (w/w) to about 7% (w/w).
9. The composition according to claim 7, wherein glycerol is present in the pharmaceutical composition in a weight percent ranging from about 0.05 to about 5% (w/w).
10. The composition according to any one of claims 1 to 9, having osmolality in the range from
- 30 about 200 to about 600 mOsm.
11. The composition according to claim 10, having osmolality of about 300 mOsm.
12. The composition according to any one of claims 1 to 11, having a pH of about 5-8.

13. The composition according to any one of claims 2 to 13, wherein the weight ratio between the liposomes and mannitol ranges from about 6:1 to about 2:1.
14. The composition according to any one of claims 1 to 13, wherein said liposomes are multilamellar vesicles (MLV).
- 5 15. The composition according to any one of claims 1 to 14, wherein said GPL comprises two C₁₄, C₁₅, C₁₆ or C₁₈ acyl chains.
16. The composition according to any one of claims 1 to 15, wherein at least one of said hydrocarbon chains is a saturated hydrocarbon chain.
17. The composition according to claim 16, wherein the two hydrocarbon chains are saturated.
- 10 18. The composition according to any one of claims 1 to 17, wherein said PL is a phosphatidylcholine (PC).
19. The composition according to claim 18, wherein said at least one membrane comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).
20. The composition according to claim 19, wherein said at least one membrane further
15 comprises a PC selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (C15), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and a SM having a C₁₆ hydrocarbon chain (D-*erythro* C16).
21. The composition according to claim 20, wherein the mole percent of DMPC in the at least
20 one membrane ranges from about 10% to about 75%.
22. The composition according to claim 20, wherein said at least one membrane comprises DMPC and DPPC.
23. The composition according to claim 22, wherein the mole percent ratio of DMPC to DPPC is in the range of about 25:75 to about 70:30.
- 25 24. The composition according to claim 23, wherein the mole percent ratio of DMPC to DPPC is about 45:55.
25. The composition according to claim 20, wherein said at least one membrane comprises DMPC and C15.
26. The composition according to claim 25, wherein the mole percent ratio of DMPC to C15 is
30 in the range of about 25:75 to about 45:55.
27. The composition according to claim 20, wherein said at least one membrane comprises DMPC and DSPC.

28. The composition according to claim 27, wherein the mole percent ratio of DMPC to DSPC is about 75:25.
29. The composition according to claim 20, wherein said at least one membrane comprises DMPC and D-*erythro* C16.
- 5 30. The composition according to claim 29, wherein the mole percent ratio of DMPC to D-*erythro* C16 is in the range of about 10:90 to about 25:75.
31. The composition according to claim 18, wherein said at least one membrane comprises C15.
32. The composition according to any one of claims 1 to 31, wherein the total PL concentration ranges from about 50 to about 300 mM.
- 10 33. The composition according to any one of claims 1 to 32, wherein the phospholipids are present in the pharmaceutical composition in a weight percent ranging from about 0.5% (w/w) to about 30% (w/w) of the total weight of the pharmaceutical composition.
34. The composition according to any one of claims 1 to 33, wherein the liposomes have a mean diameter of between about 0.5 μm to about 10 μm .
- 15 35. The composition according to any one of claims 1 to 34, wherein the at least one membrane has the phase transition temperature of about 30°C to about 35°C.
36. The composition according to any one of claims 1 to 35, wherein the joint temperature is in the range of about 1 – 15 °C above said phase transition temperature.
37. The composition according to any one of claims 1 to 36, being essentially free of hyaluronic acid.
- 20 38. The composition according to claim 1, comprising MLV liposomes which membranes consist essentially of DMPC and DPPC; mannitol; and histidine buffer, wherein DMPC is present in the pharmaceutical composition in a weight percent ranging from about 1% (w/w) to about 10% (w/w), DPPC is present in a weight percent ranging from about 2% (w/w) to about 12% (w/w), and mannitol is present in a weight percent ranging from about 1% (w/w) to about 7% (w/w), of the total weight of the pharmaceutical composition.
- 25 39. The composition according to any one of claims 1 to 38, wherein one dosage unit of the pharmaceutical composition comprises from about 20 mg to about 350 mg mannitol and from about 50 mg to about 1000 mg phospholipids.
- 30 40. The composition according to any one of claims 1 to 39, being in a form of a parenteral pharmaceutical composition comprising a suspension of liposomes.

41. The composition according to any one of claims 1 to 40, wherein the composition is in a form suitable for administration selected from the group consisting of intra-articular injection, arthroscopic administration and surgical administration.
42. The composition according to any one of claims 1 to 41, wherein the lubrication is for the treatment, management or prevention of an articular disorder or condition or symptoms arising therefrom.
43. The composition according to claim 42, wherein said articular disorder or condition is selected from the group consisting of arthritis, osteoarthritis, osteoarthritis in rheumatoid arthritis patients, traumatic joint injury, locked joint, sports injury, traumatic injury towards osteoarthritis (OA), joint following arthrocentesis, arthroscopic surgery, open joint surgery, joint replacement, and psoriatic arthritis.
44. The composition according to any one of claims 1 to 43, for the reduction of knee joint pain in osteoarthritis patients.
45. The composition according to any one of claims 1 to 41, wherein the lubrication is for preventing joint wear.
46. A method for lubricating a joint of a mammal, the method comprising: administering into a cavity of the joint a pharmaceutical composition comprising:
- a non-ionic tonicity agent, comprising a polyol; and
 - liposomes consisting essentially of at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C;
- the pharmaceutical composition being essentially free of an additional pharmaceutically active agent,
- wherein the joint has a joint temperature which is above the phase transition temperature.
47. A method for the treatment of pain or irritation in a joint of a subject having an articular disorder, the method comprising lubricating a joint of said subject by administering into a cavity of the joint a pharmaceutical composition comprising:
- a non-ionic tonicity agent, comprising a polyol; and
 - liposomes consisting essentially of at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two

C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, wherein the at least one membrane has a phase transition temperature in the range of about 20°C to about 39°C;
the pharmaceutical composition being essentially free of an additional pharmaceutically active agent,
wherein the joint has a joint temperature which is above the phase transition temperature.




FIGURE 1




FIGURE 2




FIGURE 3

3/7




FIGURE 4




FIGURE 5A




FIGURE 5B




FIGURE 6




FIGURE 7A




FIGURE 8A




FIGURE 7B




FIGURE 8B

5/7




FIGURE 9A




FIGURE 9B




FIGURE 10B

FIGURE 10A




FIGURE 11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2018/050923

A. CLASSIFICATION OF SUBJECT MATTER IPC (2018.01) A61L 27/50, A61K 9/00, A61K 9/127, A61K 31/685 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC (2018.01) A61L 27/50, A61K 9/00, A61K 9/127, A61K 31/685 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See extra sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008038292 A2 HADASIT MED RES SERVICE [IL], et al. 3 April 2008 03 Apr 2008 (2008/04/03) claims	1-47
A	WO 03000190 A2 DEPUY [GB], et al 03 Jan 2003 (2003/01/03) page 7, lines 4-9; page 9, lines 1-24; page 15, lines 4-22; page 17, lines 15-25; claims 1, 7, 8, 14-16	1-47
A	WO 2004047792 A2 NOVOSOM AG. [DE], et al, 10 Jun 2004 (2004/06/10) page 7, line 27 - page 10, line 3; page 11, line 27 - page 12, line 5; claims 4, 14	1-47
A	WO 02078445 A1 SCRIPPS RESEARCH INST [US], et al 10 Oct 2002 (2002/10/10) page 4, lines 13-20; page 17, lines 16-24; claims 4, 9, 10, 12, 19, 22, 24	1-47
A	US 2006029655 A1 YISSUM RES DEV CO. [IL] 09 Feb 2006 (2006/02/09) paragraphs [0057]-[0068], [0105]; claims 80-85	1-47
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 15 Nov 2018		Date of mailing of the international search report 15 Nov 2018
Name and mailing address of the ISA: Israel Patent Office Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Facsimile No. 972-2-5651616		Authorized officer NAHAMANI Moshe Telephone No. 972-2-5651739

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2018/050923

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2009024670 A2 GAVARD MOLLIARD SAMUEL [FR] 26 Feb 2009 (2009/02/26) page 1	1-47
A	WO 2012001679 A1 SEGAL DAVID [IL] 05 Jan 2012 (2012/01/05) page 1	1-47
A	WO 2012143876 A1 ANTEIS SA [CH], et al 26 Oct 2012 (2012/10/26) claim 1	1-47

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2018/050923

Patent document cited search report			Publication date	Patent family member(s)			Publication Date
WO	2008038292	A2	03 Apr 2008	WO	2008038292	A2	03 Apr 2008
				WO	2008038292	A3	12 Feb 2009
				CA	2664944	A1	03 Apr 2008
				CA	2664944	C	14 Jun 2016
				CN	101541308	A	23 Sep 2009
				CN	101541308	B	01 Feb 2012
				EP	2079442	A2	22 Jul 2009
				EP	2079442	B1	27 Jul 2016
				ES	2599630	T3	02 Feb 2017
				IL	197827	D0	24 Dec 2009
				IL	197827	A	29 Feb 2016
				JP	2010540406	A	24 Dec 2010
				JP	5660561	B2	28 Jan 2015
				US	2010098749	A1	22 Apr 2010
				US	8895054	B2	25 Nov 2014
				US	2015037404	A1	05 Feb 2015
WO	03000190	A2	03 Jan 2003	WO	03000190	A2	03 Jan 2003
				WO	03000190	A3	06 Mar 2003
				CA	2451245	A1	03 Jan 2003
				EP	1406571	A2	14 Apr 2004
				EP	1406571	A4	30 May 2007
				JP	2004535434	A	25 Nov 2004
				US	2005123593	A1	09 Jun 2005
WO	2004047792	A2	10 Jun 2004	WO	2004047792	A2	10 Jun 2004
				WO	2004047792	A3	12 Aug 2004
				AT	445389	T	15 Oct 2009
				AU	2003294635	A1	18 Jun 2004
				AU	2003294635	A2	18 Jun 2004
				AU	2003294635	B2	28 May 2009

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2018/050923

Patent document cited search report			Publication date	Patent family member(s)		Publication Date
				AU	2003294635 B8	17 Sep 2009
				CA	2507316 A1	10 Jun 2004
				CN	1731981 A	08 Feb 2006
				CN	1731981 B	16 Jun 2010
				DE	10255106 A1	09 Jun 2004
				DE	50312034 D1	26 Nov 2009
				EP	1581185 A2	05 Oct 2005
				EP	1581185 B1	14 Oct 2009
				JP	2006509750 A	23 Mar 2006
				US	2006147511 A1	06 Jul 2006
WO 02078445 A1			10 Oct 2002	WO	02078445 A1	10 Oct 2002
				AT	424111 T	15 Mar 2009
				AU	2002255993 B2	01 May 2008
				CA	2442146 A1	10 Oct 2002
				CN	1499929 A	26 May 2004
				DE	60231385 D1	16 Apr 2009
				EP	1379135 A1	14 Jan 2004
				EP	1379135 A4	03 Aug 2005
				EP	1379135 B1	04 Mar 2009
				ES	2322985 T3	03 Jul 2009
				JP	2005500991 A	13 Jan 2005
				MX	PA03008812 A	15 Oct 2004
				NZ	528544 A	31 Mar 2006
US 2006029655 A1			09 Feb 2006	US	2006029655 A1	09 Feb 2006
				AU	2002311616 B2	22 Nov 2007
				CA	2451091 A1	03 Jan 2003
				EP	1404298 A2	07 Apr 2004
				IL	159334 A	30 Dec 2010
				IL	159334 D0	01 Jun 2004

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2018/050923

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
		JP 2005525992 A	02 Sep 2005
		WO 03000227 A2	03 Jan 2003
		WO 03000227 A3	13 Nov 2003
<hr/>			
WO 2009024670 A2	26 Feb 2009	WO 2009024670 A2	26 Feb 2009
		WO 2009024670 A3	23 Apr 2009
		BR PI0813011 A2	23 Dec 2014
		CA 2691600 A1	26 Feb 2009
		CA 2691600 C	10 Jan 2017
		CN 101686936 A	31 Mar 2010
		CN 104825482 A	12 Aug 2015
		EP 2173324 A2	14 Apr 2010
		FR 2918276 A1	09 Jan 2009
		FR 2918276 B1	22 Jan 2010
		JP 2010531863 A	30 Sep 2010
		JP 5517133 B2	11 Jun 2014
		KR 20100028582 A	12 Mar 2010
		US 2010184720 A1	22 Jul 2010
		US 9138405 B2	22 Sep 2015
		US 2015352143 A1	10 Dec 2015
		US 10028976 B2	24 Jul 2018
<hr/>			
WO 2012001679 A1	05 Jan 2012	WO 2012001679 A1	05 Jan 2012
		CA 2803257 A1	05 Jan 2012
		EP 2588080 A1	08 May 2013
		EP 2588080 A4	07 Jan 2015
		EP 2588080 B1	16 May 2018
		ES 2679279 T3	23 Aug 2018
		IL 206739 D0	30 Dec 2010
		IL 206739 A	30 Jun 2016
		JP 2016153416 A	25 Aug 2016

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IL2018/050923

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
		JP 6166811 B2	19 Jul 2017
		JP 2013529679 A	22 Jul 2013
		KR 20130135731 A	11 Dec 2013
		KR 101842295 B1	27 Mar 2018
		US 2017112782 A1	27 Apr 2017
		US 9707190 B2	18 Jul 2017
		US 2013289131 A1	31 Oct 2013
		US 9913808 B2	13 Mar 2018
<hr/>			
WO 2012143876 A1	26 Oct 2012	WO 2012143876 A1	26 Oct 2012
		US 2014038917 A1	06 Feb 2014
<hr/>			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2018/050923

B. FIELDS SEARCHED:

* Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases consulted: PATENTSCOPE, USPTO, THOMSON INNOVATION, Eponline, Esp@cenet, Google Patents, CAPLUS, EPODOC, Google Scholar

Search terms used: lubrication of joints; static friction coefficient; non-ionic tonicity agent; polyol (mannitol, glycerol); liposomes [multilamellar vesicles (MLV)]; membrane; phospholipid [phosphatidylcholine (PC), (DMPC), (DPPC), (C15), (DSPC), (D-erythro C16)]; glycerophospholipid (GPL); hydrocarbon chains; sphingomyelin (SM); phase transition temperature; friction coefficient